Sample preparation compositions, devices, systems and methods

Abstract

The present disclosure relates to compositions, devices, apparatus, methods, kits, and systems for sample preparation (e.g., separation, reduction, or removal of small molecules from biomolecules in a sample). Exemplary small molecules that can be separated, reduced, or removed have a molecular weight range of less than 2000 Da and may include, but are not limited to, dyes, biotin, affinity tags, crosslinkers, reducing agents, labels, nanoparticles, radioligands, mass tags, unreacted molecules, and combinations, intermediates, and derivatives of the foregoing. Exemplary biomolecules present in a sample include, but are not limited to, proteins, glycoproteins, antibodies, peptides, nucleic acids, polysaccharides, carbohydrates, and lipids. The disclosed methods, compositions, kits, devices, apparatus, and systems can advantageously provide superior separation of small molecule contaminants and further reduce the time and costs associated with separating small molecules from larger biomolecules in a sample. Biomolecules separated as described herein are better suited for downstream processing.

Description

[Technical Field]

[0001] The present specification relates to compositions, devices, apparatus, methods, kits, and systems for sample preparation (e.g., separation of small molecules from larger molecules). In some embodiments, the compositions, apparatus, devices, systems, methods, and kits described herein can be used to separate, extract, purify, reduce, or remove small molecules from larger molecules, such as, but not limited to, biomolecules, in a sample. [Background technology]

[0002] Sample preparation techniques for isolating biomolecules aim to extract them from other sample components and sample processing components to enable downstream analysis and processing of the biomolecules. For example, during sample preparation of biomolecules such as proteins or nucleic acids, biomolecules often need to be labeled with dyes, affinity tags, radioactive labels, mass tags, etc. In other examples, biomolecules need to be chemically modified, such as by reduction, oxidation, crosslinking, or methylation. During these processes, some amount of labeling agent or chemical remains in the sample, either as unreacted labels or chemicals or in the form of partially reacted intermediates or derivatives. These unreacted small molecules can cause several problems during downstream analysis or use of biomolecules. For example, free, unreacted fluorescent dyes that are not conjugated to proteins or nucleic acids cause background problems during fluorescent imaging of proteins or nucleic acids.

[0003] Another example is the preparation of tagged antibodies (e.g., biotinylated antibodies) that are typically used to detect corresponding antigens. Streptavidin-based carriers are used in conjunction with biotinylated antibodies to detect the antigen. If free, unreacted biotin is present in the biotinylated antibody sample, it will interact with the streptavidin carrier and reduce the binding capacity of the biotinylated antibody.

[0004] Some methods used to address the removal of small molecules, such as labels and chemicals, from larger molecules, such as biomolecules, include dialysis in combination with ion exchange chromatography, size exclusion chromatography, or desalting resins in combination with ion exchange resins. However, each of these methods has some drawbacks.

[0005] For example, dialysis is commonly used to remove unreacted dyes, biotin, and reducing agents from proteins. However, dialysis requires two to three buffer exchanges and can take 12 to 14 hours to remove small molecules.

[0006] Size-exclusion chromatography is another method used to remove small molecules. This procedure requires complex and expensive chromatography equipment (such as the AKTA system or GE). In these complex chromatography systems, samples containing small molecules are passed through specific columns customized and configured for specific purposes and sample types. Typically, customized columns of 1 ml, 5 ml, 10 ml, or larger are configured depending on the sample size. Large biomolecules, such as antibody conjugates, are first rejected by the column, followed by smaller molecules that pass through the pores. Therefore, small molecules require more time to elute from the column. The time required to perform size-exclusion chromatography can vary from 30 minutes to several hours, depending on column size, setup time, etc. Therefore, size-exclusion chromatography is expensive and time-consuming.

[0007] Yet other procedures use desalting resins, where various resins are used for buffer exchange and desalting, although desalting resins have very limited capacity to remove small molecules such as dyes, labels, and conjugates (as will be shown later in this specification).

[0008] Ion exchange resins combined with desalting resins or dialysis have been used to separate small molecules that interact with the ion exchangers on the resin. However, in addition to the drawbacks of dialysis and desalting resin-based methods listed above, the protein recovery rate of ion exchange resins is low because the protein needs to be eluted from the ion exchanger. The ion exchange method for protein elution requires multiple steps, which, when combined with the need for additional dialysis or desalting resins, makes the process time-consuming and tedious.

[0009] Thus, there is a need for better methods, compositions, systems, and devices for separating larger biomolecules or larger molecules from small molecules such as free dyes, labels, reducing agents, crosslinkers, etc. that would allow for cleaner downstream processing of biomolecules in methods such as, but not limited to, fluorescence imaging, bioconjugation, immunoprecipitation, etc. Summary of the Invention

[0010] In some embodiments, the present specification relates to compositions, apparatus, devices, methods, kits, and systems for sample preparation, e.g., separation of small molecules from larger molecules (such as, but not limited to, biomolecules) in a sample. In some embodiments, the compositions, apparatus, devices, systems, methods, and kits described herein can be used to separate, extract, purify, remove, reduce the amount of, or remove small molecules from larger molecules in a sample. In some embodiments, the compositions, apparatus, devices, systems, methods, and kits described herein substantially reduce the amount of small molecules from biomolecules or larger molecules in a sample. In some embodiments, the compositions, apparatus, devices, systems, methods, and kits described herein rapidly reduce the amount of small molecules from biomolecules or larger molecules in a sample. The terms biomolecule and larger molecule are used interchangeably herein. The term larger only relates to the small molecules being removed and does not identify or limit the biomolecule to any particular size or size range.

[0011] Some examples of one or more small molecules that can be separated, extracted, reduced or removed by the compositions, apparatus, devices, systems, methods and kits of the present disclosure include, but are not limited to, dyes, dye derivatives, biotin, biotin derivatives, crosslinking agents, reducing agents, oxidizing agents, methylating agents, protein preservatives, labels, nanoparticles, radioligands, mass tags, unreacted molecules and combinations, intermediates and derivatives thereof.

[0012] Dyes suitable for use are known to those skilled in the art and include coumarins, cyanines, benzofurans, quinolines, quinazolinones, indoles, benzazoles, borapolyazaindacenes, and xanthenes, including fluoresceins, rhodamines, and rhodols, as well as those described in RICHARD P. HAUGLAND, MOLECULAR PROBES HANDBOOK OF FLUORESCENT PROBES AND RESEARCH CHEMICALS (1998) and RICHARD P. HAUGLAND, MOLECULAR PROBES HANDBOOK OF FLUORESCENT PROBES AND RESEARCH CHEMICALS (2001 ... th Other dyes include, but are not limited to, those described in the "Pigment Coloring Book" (Pigment Coloring Book, January 2010).

[0013] In some embodiments, small molecules that may be separated by the compositions, apparatus, devices, systems, methods and kits of the present disclosure have a molecular weight range of less than 2000 Da.

[0014] Exemplary larger molecules that can be separated from small molecules by the disclosed compositions, apparatus, devices, systems, methods, and kits include, but are not limited to, proteins, glycoproteins, antibodies, peptides, nucleic acids (DNA, genomic DNA, pDNA), RNA, polysaccharides, carbohydrates, lipids, toxins, nanoparticles, and derivatives of each of the molecules listed above. Derivatives of molecules include, but are not limited to, tagged proteins or tagged nucleic acids, labeled molecules labeled with various labels such as, but not limited to, dyes, fluorescent dyes, radioactive labels, affinity labels, mass tags, and metals, conjugated molecules including conjugated antibodies, molecules conjugated to nanoparticles such as gold nanoparticles, molecules conjugated to toxins such as biotin-labeled toxins, exemplified by the non-limiting example of a cholera toxin-labeled compound, chemical derivatives of biomolecules such as, but not limited to, reduced proteins, oxidized proteins, methylated nucleic acids, and proteins with sulfhydryl-modified proteins. In some embodiments, larger molecules and biomolecules can be included in a sample.

[0015] One embodiment of the present disclosure relates to a composition for separating or extracting one or more small molecules from a sample. In some embodiments, the composition comprises (at least one) size-exclusion carrier and at least one moiety capable of binding one or more small molecules to separate them from the remainder of the sample.

[0016] In some embodiments, contacting a sample with a composition of the present disclosure substantially reduces the amount of one or more small molecules from the sample.

[0017] Larger molecules present in the sample are size-excluded by the compositions of the present disclosure, while one or more small molecules remain bound to the composition via at least one moiety.

[0018] In some embodiments, contacting a sample with a composition of the present disclosure includes, but is not limited to, one or more of the following: applying the sample to the composition, passing the sample through the composition, causing the sample to flow through the composition by gravity or by using rotational or centrifugal force, creating a positive or negative pressure differential to move the sample within the composition.

[0019] In some embodiments, in the composition of the present disclosure, at least one moiety is bound to a size-exclusion carrier.In some embodiments, in the composition of the present disclosure, at least one moiety is immobilized on a size-exclusion carrier.In some embodiments, in the composition of the present disclosure, at least one moiety is attached to a size-exclusion carrier.

[0020] In some embodiments, at least one moiety is associated with one or more small molecules by charge interactions, hydrophilic interactions, hydrophobic interactions, affinity interactions, hydrogen bonds, van der Waals forces, or covalent bonds.

[0021] In some embodiments, compositions of the present disclosure may include at least two parts, or at least three parts, or at least four parts, or at least five parts, etc.

[0022] In some embodiments, the size exclusion carrier used in the compositions of the present disclosure excludes molecules equal to or greater than 2 kDa from the sample. In some embodiments, the size exclusion carrier used in the compositions of the present disclosure excludes molecules equal to or greater than 3 kDa from the sample.

[0023] In some embodiments, the composition of the present disclosure may comprise two or more size exclusion carriers. For example, the composition may comprise at least a second size exclusion carrier and at least a second portion. In some embodiments, the composition of the present disclosure may further comprise a third size exclusion carrier, a fourth size exclusion carrier, a fifth size exclusion carrier, etc.

[0024] Each exclusion carrier can be bound to the same or different moieties. For example, in some embodiments, a first size exclusion carrier can be bound to one or more moieties, such as a first moiety, a second moiety, a third moiety, a fourth moiety, a fifth moiety, etc. In other exemplary embodiments, a first size exclusion carrier can be bound to a first moiety, a second size exclusion carrier can be bound to a second moiety, a third size exclusion carrier can be bound to a third moiety, a fourth size exclusion carrier can be bound to a fourth moiety, a fifth size exclusion carrier can be bound to a fifth moiety, etc. Other combinations are also contemplated.

[0025] In some embodiments, the composition of the present disclosure can comprise various combinations of size exclusion carriers and moieties in different ratios.For example, the composition can comprise a ratio of a first size exclusion carrier and at least a first moiety to one or more additional moieties or one or more additional size exclusion carriers and moieties.In another example, the composition can comprise a ratio of a first size exclusion carrier and a first moiety to at least a second size exclusion carrier and at least a second moiety.

[0026] The compositions of the present disclosure may also include blends of exclusion carriers and moieties, such as a blend of a first size-exclusion carrier and a first moiety and a second size-exclusion carrier and a second moiety, or even a blend of a first size-exclusion carrier and a first moiety, a second moiety (and a third moiety, etc.). Compositions including various combinations of one or more size-exclusion carriers and one or more moieties are contemplated.

[0027] In some embodiments, one or more portions of the compositions of the present disclosure may comprise polysaccharides, dextran, polyethylene glycol polymers, amine-containing polymers, polyamino acids, antibiotics, chelating groups, magnetic particles, paramagnetic particles, functional groups, ion exchangers, and combinations thereof.

[0028] In some embodiments, the amine-containing polymer of the disclosed compositions is poly(ethylene glycol)diamine, polyethylenediamine, linear polyethyleneimine, or branched polyethyleneimine. In some embodiments, the linear polyethyleneimine is diethylenediamine.

[0029] In some embodiments of the compositions of the present disclosure, at least one moiety is dextran. Various dextrans can be used. In some embodiments, the dextran used in the compositions of the present disclosure has a molecular weight ranging from about 6 kDa to 2800 kDa. In some embodiments, the dextran used in the compositions of the present disclosure has a molecular weight ranging from about 1500 kDa to 2800 kDa.

[0030] In some embodiments, the moiety used in the composition of the present disclosure is an ion exchanger. The ion exchanger is an anion exchanger or a cation exchanger. Non-limiting examples of ion exchangers include negatively charged hydroxyl groups and positively charged pentylamine, diamine, and imine groups.

[0031] In some embodiments, moieties used in compositions of the present disclosure are polyamino acids, such as polylysine, polyhistidine, and / or polyglutamic acid.

[0032] In some non-limiting exemplary embodiments, a composition of the present disclosure may include a first size-exclusion carrier conjugated to a first moiety, the first moiety comprising, for example, an amine-containing polymer (e.g., polyethylene glycol diamine), and a second size-exclusion carrier conjugated to a second moiety, the second moiety comprising, for example, dextran.

[0033] In some other non-limiting exemplary embodiments, the compositions of the present disclosure may include a first size-exclusion carrier bound to, for example, poly(ethylene glycol) diamine, polyethyleneimine, linear polyethyleneimine, or branched polyethyleneimine, and a second size-exclusion carrier bound to a second moiety, for example, comprising dextran.

[0034] In some other non-limiting exemplary embodiments, compositions of the present disclosure may include at least a first size-exclusion carrier bound to a first moiety comprising poly(ethylene glycol) diamine, and the first or second size-exclusion carrier bound to a second moiety, the second moiety comprising dextran.

[0035] In some other non-limiting exemplary embodiments, the compositions of the present disclosure may include a first size-exclusion carrier coupled to a first moiety comprising N,N-diethylethylenediamine, and a second size-exclusion carrier coupled to a second moiety, the second moiety comprising, for example, dextran.

[0036] In some non-limiting exemplary embodiments, the compositions of the present disclosure can include a first size-exclusion carrier conjugated to a first moiety comprising, for example, an amine-containing polymer, and a second size-exclusion carrier conjugated to a second moiety comprising, for example, a polyethylene glycol polymer.

[0037] The compositions described herein are included in the devices, apparatus, systems and kits of the present disclosure and are used in one or more of the methods of the present disclosure, which are described in more detail in the following sections.

[0038] In some embodiments, the present disclosure provides an apparatus and / or device for separating, removing, or extracting one or more small molecules from a sample, the apparatus and / or device comprising: a) a container containing at least one size-exclusion carrier and at least one moiety capable of binding to one or more small molecules; and b) a receptacle located below the container.

[0039] In some embodiments, the present disclosure provides a system for separating, removing, or extracting one or more small molecules from a sample, the system comprising: a) a container comprising at least one size-exclusion carrier and at least one moiety capable of binding one or more small molecules; and b) a receptacle positioned below the container. The system of the present disclosure is configured to apply a force, such as, but not limited to, vacuum, gravity, negative pressure, or positive pressure, to the sample in the container. In some embodiments, the system of the present disclosure includes a means for applying a force, such as, but not limited to, vacuum, gravity, negative pressure, or positive pressure, to the receptacle and container combination.

[0040] In some embodiments of the disclosed devices, apparatus, or systems, a receptacle is attached to the column. In some embodiments, the receptacle is removable from the column. The contents of the receptacle can be removed by the user. The receptacle of the device collects a sample that is substantially depleted of small molecules. The disclosed devices, devices, or systems are operable to separate, reduce, or remove one or more small molecules from a sample in a single step. The disclosed devices, apparatus, or systems are operable to apply a force to the sample in the container, such as, but not limited to, vacuum, gravity, negative pressure, or positive pressure.

[0041] Some embodiments of the disclosed devices, apparatus, or systems are operatively configured to be subjected to gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, and combinations thereof.

[0042] In some embodiments of the disclosed devices, apparatus, or systems, the vessel is a columnar vessel, a tube, a multi-well tube, a multi-well plate, or a multi-well filter plate. Exemplary vessels include, but are not limited to, spin columns, multi-well plates, multi-well filter plates, microwell plates, and microwell filter plates.

[0043] The systems, apparatus and devices of the present disclosure, in embodiments, comprise a container containing one or more of the compositions of the present disclosure as described in the sections above and below.

[0044] In some embodiments, the present disclosure describes a kit for separating a biomolecule from one or more small molecules, the kit including a device including: a) a container containing a size exclusion resin and at least one moiety capable of binding to and capturing at least one small molecule; and b) a receptacle located below the container, wherein the device is configured to be operatively subjected to gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, and combinations thereof.

[0045] The kits of the present disclosure can include one or more of the compositions, devices, apparatus, and / or systems described herein. In some embodiments, the kits of the present disclosure include at least two or more moieties capable of binding to one or more small molecules.

[0046] In some embodiments of the kit of the present disclosure, the device is a spin column, a multi-well filter plate, or a multi-well plate. The kit may further include one or more buffers packaged in one or more separate containers or contained in the first container.

[0047] In some embodiments, the present disclosure describes a method for separating biomolecules from one or more small molecules, comprising: a) applying a sample containing biomolecules to a vessel comprising a size-exclusion carrier and at least one moiety capable of binding to one or more small molecules; and b) subjecting the vessel to gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, or a combination thereof, wherein biomolecules in the sample are excluded by the size-exclusion carrier and collected as flow-through, and one or more small molecules bind to the at least one moiety and are thereby separated from the biomolecules.

[0048] In some embodiments of the disclosed methods, separation of at least one small molecule from the remainder of the sample is performed in one step. In some embodiments of the disclosed methods, the flow-through is collected in a receptacle located below the vessel.

[0049] The disclosed methods, compositions, kits, devices, apparatus, and systems advantageously provide superior separation of small molecules and further reduce the time and costs associated with separating small molecules from larger biomolecules in a sample. Larger biomolecules separated as described herein are better suited for downstream processing. While certain advantages have been disclosed above, it will be understood that various embodiments may include all, some, or none of the previously disclosed advantages. Other technical advantages may be readily apparent to those skilled in the art in light of the teachings of the present disclosure.

[0050] These and other features of the present teachings will become more apparent from the detailed description in the following sections. [Brief explanation of the drawings]

[0051] One or more embodiments of the present disclosure may be better understood with reference to one or more of the following drawings. Those skilled in the art will understand that the drawings described below are for illustrative purposes only. The drawings are not intended to limit the scope of the present teachings in any way.

[0052] [Figure 1A] 1 illustrates a schematic diagram of a size-exclusion carrier to which a moiety may be attached to form an exemplary composition according to one embodiment of the present disclosure. [Figure 1B] 1 illustrates a schematic diagram of a composition of the present disclosure binding to one or more small molecules, according to one embodiment of the present disclosure. [Figure 2A] FIG. 1 illustrates a schematic diagram of a non-limiting exemplary composition of the present disclosure, according to one embodiment of the present disclosure. [Figure 2B] FIG. 1 illustrates a schematic diagram of a non-limiting exemplary composition of the present disclosure, according to one embodiment of the present disclosure. [Figure 2C]FIG. 1 illustrates a schematic diagram of a non-limiting exemplary composition of the present disclosure, according to one embodiment of the present disclosure. [Figure 2D] FIG. 1 illustrates a schematic diagram of a non-limiting exemplary composition of the present disclosure, according to one embodiment of the present disclosure. [Figure 2E] FIG. 1 illustrates a schematic diagram of a non-limiting exemplary composition of the present disclosure, according to one embodiment of the present disclosure. [Figure 2F] FIG. 1 illustrates a schematic diagram of a non-limiting exemplary composition of the present disclosure, according to one embodiment of the present disclosure. [Figure 3] 1 illustrates a three-dimensional (3D) view of an exemplary apparatus or device, according to one embodiment of the present disclosure. [Figure 4A] 1 illustrates a three-dimensional (3D) view of an exemplary apparatus or device, according to one embodiment of the present disclosure. [Figure 4B] 1 illustrates a three-dimensional (3D) view of an exemplary apparatus or device, according to one embodiment of the present disclosure. [Figure 5] 1 illustrates the removal of an exemplary small molecule, free dye, using compositions, devices, kits and methods according to one embodiment of the present disclosure. [Figure 6] 1 illustrates the removal of an exemplary small molecule, free dye, using compositions, devices, kits and methods according to one embodiment of the present disclosure. [Figure 7] 1 illustrates the removal of an exemplary small molecule, a reducing agent, using compositions, devices, kits and methods according to one embodiment of the present disclosure. [Figure 8] 1 illustrates the removal of an exemplary small molecule, free dye, using a blend composition, device, kit and method according to one embodiment of the present disclosure. [Figure 9] 1 illustrates the removal of an exemplary small molecule, free dye, using a blend composition, device, kit and method according to one embodiment of the present disclosure. [Figure 10] 1 illustrates the removal of an exemplary small molecule, free dye, using a blend composition, device, kit and method according to one embodiment of the present disclosure. [Figure 11]1 illustrates the removal of an exemplary small molecule, free dye, using a blend composition, device, kit and method according to one embodiment of the present disclosure. [Figure 12] 1 illustrates the removal of an exemplary small molecule, two exemplary free dyes, using a blend composition, device, kit and method according to one embodiment of the present disclosure. [Figure 13] 1 illustrates exemplary small molecule, reducing agent removal, and corresponding protein recovery using blend compositions, devices, kits, and methods according to one embodiment of the present disclosure. [Figure 14] 1 illustrates the removal of an exemplary small molecule, free biotin, and recovery of the corresponding protein using a blend composition, device, kit, and method according to one embodiment of the present disclosure. [Figure 15] FIG. 13 illustrates quantitative data for removal of an exemplary small molecule, free dye Alexa Fluor™ 555, and protein recovery using a blend composition, device, kit, and method according to one embodiment of the present disclosure. [Figure 16] FIG. 12 illustrates quantitative data for removal of exemplary small molecules, free dye fluorescein, and protein recovery using blend compositions, devices, kits, and methods according to one embodiment of the present disclosure. [Figure 17] 1 illustrates the removal of an exemplary small molecule, BS3, bis(sulfosuccinimidyl) suberate, and protein recovery using blend compositions, devices, kits, and methods according to one embodiment of the present disclosure. [Figure 18] Illustrates the removal of an exemplary small molecule, SMCC, (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate), and protein recovery using blend compositions, devices, kits, and methods according to one embodiment of the present disclosure. [Figure 19] 1 illustrates the removal of an exemplary small molecule, DTT (dithiothreitol), and protein recovery using a blend composition, device, kit, and method according to one embodiment of the present disclosure. [Figure 20A]Illustrates the removal of an exemplary small molecule, free dye Alexa Fluor™ 647, and protein recovery using a composition, device, kit, and / or method according to one embodiment of the present disclosure, compared to small molecule removal and protein recovery by other existing products sold for similar uses. [Figure 20B] Illustrates the removal of an exemplary small molecule, free dye Alexa Fluor™ 647, and protein recovery using a composition, device, kit, and / or method according to one embodiment of the present disclosure, compared to small molecule removal and protein recovery by other existing products sold for similar uses. [Figure 21] Illustrates exemplary small molecule, biotin removal, and protein recovery using compositions, devices, kits, and / or methods according to one embodiment of the present disclosure, compared to small molecule removal and protein recovery by other existing products sold for similar uses. [Figure 22] Illustrates the removal of an exemplary small molecule, the reducing agent TCEP, using compositions, devices, kits and methods according to one embodiment of the present disclosure, compared to the removal of reducing agents by other existing products sold for similar uses. [Figure 23] Illustrates the removal of exemplary small molecules, free dye Alexa Fluor™ 647, and protein recovery using compositions, spin column devices, kits, and methods according to one embodiment of the present disclosure compared to the use of existing dialysis methods for removing Alexa Fluor™ 647 dye. [Figure 24] Illustrates exemplary small molecule, biotin removal, and protein recovery using compositions, devices, kits, and methods according to one embodiment of the present disclosure compared to existing dialysis methods for biotin removal. [Figure 25] 1 illustrates the removal of an exemplary small molecule, free dye Alexa Fluor™ 647, and protein recovery using compositions, spinplate devices, kits, and methods according to one embodiment of the present disclosure. [Figure 26]1 illustrates exemplary small molecule, free fluorescein dye removal, and protein recovery using compositions, spin column devices, kits, and methods according to one embodiment of the present disclosure. [Figure 27A] Immunofluorescence images of exemplary cells stained with a polyclonal antibody-Alexa Fluor™ 647 conjugate are shown, compared to immunofluorescence images of the same cells without cleanup (by not using a spin column of the present disclosure) (Figure 27B), demonstrating the removal of excess free dye, Alexa Fluor™ 647, by cleanup using a spin column containing a composition of the present disclosure (Figure 27A). [Figure 27B] Immunofluorescence images of exemplary cells stained with a polyclonal antibody-Alexa Fluor™ 647 conjugate are shown, compared to immunofluorescence images of the same cells without cleanup (by not using a spin column of the present disclosure) (Figure 27B), demonstrating the removal of excess free dye, Alexa Fluor™ 647, by cleanup using a spin column containing a composition of the present disclosure (Figure 27A). [Figure 28A] Immunofluorescence images of exemplary cells stained with a polyclonal antibody labeled with Alexa Fluor™ 647 are illustrated and compared with immunofluorescence images of the same cells without cleanup (by not using a spin column of the present disclosure) (Figure 28A), and further compared with immunofluorescence images of the same cells where cleanup was performed by using a spin column with the existing product GE PD10 (Figure 28B), demonstrating the removal of excess free dye Alexa Fluor™ 647 by cleanup using a spin column containing a composition of the present disclosure (Figure 28C). [Figure 28B]Immunofluorescence images of exemplary cells stained with a polyclonal antibody labeled with Alexa Fluor™ 647 are illustrated and compared with immunofluorescence images of the same cells without cleanup (by not using a spin column of the present disclosure) (Figure 28A), and further compared with immunofluorescence images of the same cells where cleanup was performed by using a spin column with the existing product GE PD10 (Figure 28B), demonstrating the removal of excess free dye Alexa Fluor™ 647 by cleanup using a spin column containing a composition of the present disclosure (Figure 28C). [Figure 28C] Immunofluorescence images of exemplary cells stained with a polyclonal antibody labeled with Alexa Fluor™ 647 are illustrated and compared with immunofluorescence images of the same cells without cleanup (by not using a spin column of the present disclosure) (Figure 28A), and further compared with immunofluorescence images of the same cells where cleanup was performed by using a spin column with the existing product GE PD10 (Figure 28B), demonstrating the removal of excess free dye Alexa Fluor™ 647 by cleanup using a spin column containing a composition of the present disclosure (Figure 28C). [Figure 29A] Immunofluorescence images of exemplary cells stained with a monoclonal antibody labeled with Alexa Fluor™ 488 are shown, compared to immunofluorescence images of the same cells without cleanup (by not using a spin column of the present disclosure) (Figure 29A), demonstrating the removal of excess free dye, Alexa Fluor™ 488, by a spin column with a composition of the present disclosure (Figure 29B). [Figure 29B] Immunofluorescence images of exemplary cells stained with a monoclonal antibody labeled with Alexa Fluor™ 488 are shown, compared to immunofluorescence images of the same cells without cleanup (by not using a spin column of the present disclosure) (Figure 29A), demonstrating the removal of excess free dye, Alexa Fluor™ 488, by a spin column with a composition of the present disclosure (Figure 29B). [Figure 30A]1 shows a comparison of a protein recovery and dye removal composition, device and method of the present disclosure (Roomba) with an ion exchange resin (Dowex), according to one embodiment. [Figure 30B] 1 shows a comparison of a protein recovery and dye removal composition, device and method of the present disclosure (Roomba) with an ion exchange resin (Dowex), according to one embodiment. [Figure 31A] 1 shows a comparison of the protein recovery and dye removal compositions, devices and methods of the present disclosure (Roomba) with an ion exchange resin (Dowex), according to one embodiment. [Figure 31B] 1 shows a comparison of the protein recovery and dye removal compositions, devices and methods of the present disclosure (Roomba) with an ion exchange resin (Dowex), according to one embodiment. DETAILED DESCRIPTION OF THE INVENTION

[0053] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not intended to limit the scope of the present teachings. In this application, the use of the singular includes the plural unless specifically stated otherwise. For example, as used herein, the singular forms "a," "an," and "the" also include the plural unless the context dictates otherwise. Similarly, as used herein, singular terms also refer to the plural and vice versa unless the context dictates otherwise.

[0054] Also, the use of "comprise," "contain," and "include," or variations of these roots, such as "comprise," "contained," and "including," are not intended to be limiting. The use of "or" includes "and / or" unless otherwise stated. The term "and / or" means that the terms before and after the slash may be taken together or separately. By way of illustration, and not by way of limitation, "X and / or Y" may mean "X" or "Y," or "X" and "Y."

[0055] Whenever a range of values ​​is provided herein, that range is meant to include the starting and ending values, and any value or range of values ​​therebetween, unless otherwise specified. For example, "0.2 to 0.5" means ranges therebetween, such as 0.2, 0.3, 0.4, 0.5, 0.2 to 0.3, 0.3 to 0.4, 0.2 to 0.4, increments therebetween, such as 0.25, 0.35, 0.225, 0.335, 0.49, increments therebetween, such as 0.26 to 0.39, etc.

[0056] As used herein, the term "or combinations thereof" refers to all permutations and combinations of the items listed preceding the term. For example, "A, B, C, or combinations thereof" is intended to include at least one of A, B, C, AB, AC, BC, or ABC, and also includes BA, CA, CB, ACB, CBA, BCA, BAC, or CAB if order is important in a particular context. Continuing with this example, combinations including repeats of one or more items or terms, such as BB, AAA, AAB, BBC, AAABCCCC, CBBAAA, CABABB, etc., are expressly included. Those skilled in the art will understand that there is typically no limit to the number of items or terms in any combination, unless otherwise apparent from the context.

[0057] The terms "separation," "extraction," "extracted," "removal," "reduction," or "reduction in amount," or "purification" all refer to the act or process of removing or separating a substance (e.g., a small molecule such as a label or chemical, or a larger molecule or biomolecule such as DNA, RNA, or protein) from a mixture (of several components, such as cellular components, or of substances in a sample that includes small molecules and / or biomolecules and / or larger molecules). The extracted substance, or the sample from which it is extracted, has significantly reduced, substantially reduced, substantially removed, substantially pure, or pure (contaminant-free), or is concentrated or substantially enriched compared to before extraction.

[0058] The term "small molecule" generally refers to any molecule smaller than a large molecule (such as, but not limited to, a biomolecule) that is used to treat, derivatize, conjugate, crosslink, label, tag, or chemically or biologically modify a larger molecule for further analysis. Larger molecules and / or biomolecules, including proteins, glycoproteins, antibodies, nucleic acids (DNA, genomic DNA, pDNA, RNA), polysaccharides, carbohydrates, lipids, and some other larger molecules, such as toxins and nanoparticles, are often derivatized by various treatments before further analysis or use. Derivatization includes labeling a molecule with a label, such as a dye, affinity tag, radiolabel, mass tag, or metal. Derivatization also includes chemical modification of a molecule by reduction, oxidation, methylation, biological or biochemical modification of a biomolecule, etc. Derivatives of biomolecules include, but are not limited to, chemical derivatives of biomolecules such as, but not limited to, tagged proteins or nucleic acids, labeled biomolecules labeled with various labels such as, but not limited to, dyes, fluorescent dyes, radioactive labels, affinity labels, mass tags, metals, conjugated biomolecules including conjugated antibodies, biomolecules conjugated to nanoparticles, metals such as gold conjugated to nanoparticles, dyes or labels such as biotin bound to toxins, reduced proteins, oxidized proteins, methylated nucleic acids, sulfhydryl-modified proteins, and other proteins.

[0059] Derivatization methods often leave "small molecule" by-products in the sample, including (but not limited to) unreacted free label, partially reacted label, derivatives of unreacted free label including free dye, dye derivatives, free radioligand, radioligand intermediates, free mass tags, free metals, biotin, biotin derivatives, crosslinkers and their derivatives, excess reducing agents or their derivatives, unreacted nanoparticles, other unreacted, partially reacted, or intermediate molecules, and combinations, intermediates, and derivatives thereof. Because these unreacted small molecules can cause several problems during downstream analysis or use of larger molecules, it is necessary to separate, extract, remove, or reduce the amount of "small molecules" from larger molecules and their derivatives during sample preparation. In some embodiments, small molecules that can be separated, extracted, or removed by the disclosed compositions, devices, apparatus, systems, kits, and methods are typically less than 2 kDa.

[0060] The term "support" refers to an inert porous solid. The term "size-exclusion support" refers to an inert porous solid having a porosity that determines the size of molecules that can be included or excluded from entering the pores. In some embodiments, the pore size of the size-exclusion support is equal to 2 kDa. In some embodiments, the pores of the size-exclusion support of the present disclosure have a molecular size cutoff of 2 kDa, such that the molecules that are excluded are 2 kDa or larger. In some embodiments, the pore size of the size-exclusion support is greater than 2 kDa. In some embodiments, the pores of the size-exclusion support of the present disclosure have a molecular size cutoff of greater than about 2 kDa, such that the molecules that are excluded are larger than 2 kDa. In one embodiment, the pore size of the size exclusion column has a molecular size cutoff size for excluding molecules from the pores from about 2 kDa to about 150 kDa, about 5 kDa to about 150 kDa, including, but not limited to, 2 kDa, 3 kDa, 5 kDa, 7 kDa, 10 kDa, 15 kDa, 20 kDa, 30 kDa, 40 kDa, 50 kDa, 60 kDa, 70 kDa, 80 kDa, 90 kDa, 100 kDa, 110 kDa, 120 kDa, 130 kDa, 140 kDa, and 150 kDa, including ranges therebetween. In some embodiments, there is no upper limit to the size of proteins that can be excluded, and it is contemplated that megadalton-sized molecules will also be separated from small molecule impurities or contaminants by the compositions, devices, systems, kits, and methods of the present disclosure.

[0061] The chapter headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described in any way. All literature and similar materials cited in this application, including but not limited to patents, patent applications, articles, books, papers, and Internet web pages, regardless of the format of such literature and similar materials, are expressly incorporated by reference in their entirety for all purposes. In the event that one or more of the incorporated literature and similar materials defines or uses a term in a manner that contradicts the definition of that term in this application, this application controls. While the present teachings will be described in conjunction with various embodiments, it is not intended that the present teachings be limited to such embodiments. To the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be understood by those skilled in the art in light of the present teachings.

[0062] Composition: One embodiment of the present disclosure describes a composition for separating, extracting, removing, and / or reducing the amount of one or more small molecules from larger biomolecules. The composition includes a size-exclusion carrier and at least one moiety capable of binding to one or more small molecules, thereby separating the small molecules from other components (such as larger biomolecules) present in a sample.

[0063] Size-exclusion carriers typically comprise spherical beads made of gel or gel-like materials with pores. Some exemplary size-exclusion carriers are made from dextran polymers, agarose, polyacrylamide, cellulose materials, and their derivatives. The pore size range of the size-exclusion carrier determines the size of molecules that can be included in or excluded from the size-exclusion carrier.

[0064] When a sample solution is applied to the size-exclusion support, the sample solution moves down the support, causing smaller sample components to enter the pores. Sample components larger than the pore size cannot enter the pores. Therefore, the larger sample components are excluded and elute from the size-exclusion column faster than the smaller components trapped in the pores.

[0065] This composition comprises at least one size-exclusion carrier and at least one moiety that can bind to one or more small molecules.Therefore, this composition provides the separation of small molecules from the larger biomolecules of a sample by combining size exclusion, size inclusion, and separation by the binding of small molecules to at least one moiety.The inventors have found that this composition provides unexpectedly rapid, economical and efficient separation of small molecules from larger biomolecules.

[0066] In some embodiments, the compositions of the present disclosure comprise at least one moiety bound to at least one size-exclusion support. In some embodiments, the compositions of the present disclosure comprise at least one moiety immobilized on at least one size-exclusion support.

[0067] 1A shows a schematic diagram of an exemplary size-exclusion support 10, according to one embodiment of the present disclosure, coupled with a moiety 20 to form an exemplary composition 30. FIG. 1B shows a schematic diagram of composition 30 of the present disclosure coupled with one or more small molecules 40 to form a complex 50, according to one embodiment of the present disclosure.

[0068] 2A shows a schematic diagram of another non-limiting exemplary composition 30′ of the present disclosure, comprising an exemplary size-exclusion carrier 10′ coupled with a moiety 20′, according to one embodiment of the present disclosure. FIG. 2B shows yet another non-limiting exemplary composition 30″ of the present disclosure, comprising an exemplary size-exclusion carrier 10′ coupled with a moiety 20″, according to one embodiment of the present disclosure. These drawings are non-limiting exemplary configurations used to illustrate some possible configurations. In light of the description and drawings herein, one skilled in the art will understand that several other combinations of configurations are contemplated by the present disclosure.

[0069] In some embodiments, immobilization is by the formation of a covalent bond between the size-exclusion support and the moiety, such as, but not limited to, an amide bond, alkylation, amination, amidation, a covalent amine-forming bond, or a covalent amide-forming bond. In some embodiments, the size-exclusion support includes dextran polymers, agarose, polyacrylamide, cellulose materials, and their derivatives. In some exemplary embodiments, the size-exclusion support includes hydroxyethyl cellulose. In an exemplary immobilization, according to the present disclosure, hydroxyethyl cellulose can be oxidized with periodate to generate aldehyde groups. These generated aldehyde groups can react with terminal amines on exemplary moieties, such as, but not limited to, pentylamine (which can be used as a spacer molecule) or poly(ethylene glycol) bisamine, to form Schiff base intermediates. The unstable Schiff base interaction can be chemically stabilized by reduction using chemicals such as sodium cyanoborohydride to form secondary amine bonds.

[0070] In some embodiments, the pore size of the size-exclusion support is equal to or greater than 2 kDa. In these exemplary compositions, the molecules excluded from the pores are molecules that are or exceed 2 kDa. Biomolecules of 2 kDa or greater are eluted from these compositions. In some exemplary embodiments, the pore size of the size-exclusion support is greater than about 2 kDa to about 50 kDa, greater than 2 kDa to about 75 kDa, greater than 2 kDa to about 100 kDa, greater than 2 kDa to about 150 kDa, or greater than 2 kDa to about 200 kDa. In some embodiments, the pore size of the size-exclusion support is about 7000 Da to about 50,000 Da. In some embodiments, there is no upper limit to the size of proteins that can be excluded, and it is contemplated that megadalton-sized and larger molecules may also be separated from small molecule impurities or contaminants by the compositions, devices, systems, kits, and methods of the present disclosure.

[0071] In some embodiments, a composition of the present disclosure (when contacted with a sample) substantially reduces the amount of one or more small molecules from the sample. In some embodiments, contacting a sample with a composition of the present disclosure includes, but is not limited to, one or more of the following: applying the sample to the composition, passing the sample through the composition, flowing the sample through the composition by gravity or by using rotational or centrifugal force, or moving the sample through the composition by creating a pressure differential.

[0072] In some embodiments, at least one moiety is associated with one or more small molecules by charge interactions, hydrophilic interactions, hydrophobic interactions, affinity interactions, hydrogen bonds, van der Waals forces, or covalent bonds.

[0073] In some embodiments, compositions of the present disclosure can include at least two moieties, or at least three moieties, or at least four moieties, or at least five moieties, etc. FIG. 2C shows a schematic diagram of a non-limiting exemplary composition 30''' of the present disclosure, including an exemplary size-exclusion carrier 10' bound to at least two moieties 20' and 20'', according to one embodiment of the present disclosure. These figures are non-limiting exemplary configurations used to illustrate several possible combinations of different numbers of moieties. Those skilled in the art will understand, in light of the description and figures herein, that several other combinations of configurations are contemplated by the present disclosure and that the illustrations do not limit the scope of the teachings herein.

[0074] In some embodiments, the size exclusion resin excludes molecules equal to 2 kDa from the sample. In some embodiments, the size exclusion resin excludes molecules greater than 2 kDa from the sample. In some embodiments, the size exclusion resin excludes molecules greater than 3 kDa from the sample. In some embodiments, the size exclusion resin excludes molecules greater than 5 kDa from the sample.

[0075] In some embodiments, the compositions of the present disclosure may further comprise at least a second size-exclusion carrier. In some embodiments, the compositions of the present disclosure may further comprise a third size-exclusion carrier, a fourth size-exclusion carrier, a fifth size-exclusion carrier, etc. In some embodiments, the compositions of the present disclosure may further comprise at least a second portion, at least a third portion, a fourth portion, a fifth portion, etc. One size-exclusion carrier may contain one or more different types of portions. Alternatively, different size-exclusion carriers may contain the same or different types of portions.

[0076] In some embodiments, the compositions of the present disclosure comprise one or more size-exclusion carriers and one or more moieties in various combinations at different ratios, as described herein. For example, the compositions of the present disclosure comprise different ratios of a first size-exclusion carrier and at least a first moiety and a second size-exclusion carrier and at least a second moiety. Another exemplary composition of the present disclosure comprises different ratios of a first size-exclusion carrier and at least a first moiety and a first size-exclusion carrier and at least a second moiety. Yet another exemplary composition of the present disclosure comprises different ratios of a first size-exclusion carrier and at least a first moiety and a first size-exclusion carrier and at least a first and a second moiety (and a third moiety, etc.). Compositions are contemplated that can facilitate the separation or removal of one or more biomolecules or one or more small molecules present in a sample by applying the sample to a single composition.

[0077] FIG. 2D shows a schematic diagram of a non-limiting exemplary composition comprising a blend of compositions 30′ and 30″ in a ratio n:n (each n can independently be a number from 1 to 9, e.g., ratios of 1:1, 2:1:3:4; 1:5, etc.). FIG. 2E shows a schematic diagram of another non-limiting exemplary composition comprising a blend of compositions 30′″ and 30′ in a ratio n:n (each n can independently be a number from 1 to 9). FIG. 2F shows a schematic diagram of yet another non-limiting exemplary composition comprising a blend of compositions 30″ and 30′″ in a ratio n:n (each n can independently be a number from 1 to 9). These figures are non-limiting exemplary compositions used to illustrate some possible compositions. In light of the description and figures herein, one of ordinary skill in the art will understand that several other blends and combinations of compositions are contemplated by the present disclosure.

[0078] In some embodiments, one or more portions of the compositions of the present disclosure may comprise polysaccharides, polyethylene glycol polymers, amine-containing polymers, polyamino acids, antibiotics, chelating groups, magnetic particles, paramagnetic particles, functional groups, ion exchangers, and combinations thereof.

[0079] Exemplary amine-containing polymers that may be used in the compositions of the present disclosure include, but are not limited to, poly(ethylene glycol)diamine, polyethylenediamine, linear polyethyleneimine, or branched polyethyleneimine. An exemplary linear polyethyleneimine is diethylenediamine.

[0080] In some exemplary compositions of the present disclosure, one or more polysaccharide moieties can be one or more dextrans. A variety of dextrans can be used. In some embodiments, the dextrans used in the compositions of the present disclosure have a molecular weight ranging from about 6 kDa to 2800 kDa. In some embodiments, the dextrans used in the compositions of the present disclosure have a molecular weight ranging from about 1500 kDa to 2800 kDa.

[0081] In some embodiments, the moieties used in the compositions of the present disclosure are ion exchangers, such as anion exchangers or cation exchangers. Anion exchanger moieties can bind small molecules with a negative charge, leaving sample components with a positive charge. Cation exchangers can bind small molecules with a positive charge, leaving sample components with a negative charge. Non-limiting examples of ion exchangers include negatively charged hydroxyl groups, positively charged pentylamine groups, diamines, and imine groups.

[0082] In some exemplary compositions of the present disclosure, one or more polyamino acid moieties may be polylysine, polyhistidine, polyglutamine, polyasparagine, etc. In some embodiments, the polyamino acid moieties may remove or separate endotoxins from other larger biomolecules.

[0083] In some embodiments, either the size-exclusion carrier or the moiety may contain a reactive functional group. The functional group on the size-exclusion carrier may be used to interact with and bind to one or more moieties to form a composition. The functional group on the moiety may be used to interact with and bind to one or more small molecules that are separated or extracted from larger biomolecules. The functional group may include, but is not limited to, hydroxyl, carboxyl, amino, thiol, aldehyde, halogen, nitro, cyano, amide, urea, carbonate, carbamate, isocyanate, sulfone, sulfonate, sulfonamide, sulfoxide, and other groups for binding or interacting with moieties or small molecules.

[0084] In another embodiment, the functional group is R, which represents a reactive functional moiety. x or a reactive functional moiety R attached to either the size exclusion support or moiety by a covalent bond L x Represents (-LR x), which may be represented by any of the following: acrylamide, activated ester of carboxylic acid, acyl halide, acyl azide, acyl nitrile, aldehyde, alkyl halide, anhydride, aniline, aryl halide, azide, aziridine, boronate, thioboronate group, carboxylic acid, diazoalkane, haloacetamide, halotriazine, hydrazine, hydrazide, imidoester, isocyanate, isothiocyanate, maleimide, phosphoramidite, sulfonyl halide, thiol group, sulfide group, disulfide group, epoxide group, episulfide group, thioester group, alcohol group, activated alcohol group, phosphate group, phosphate ester group, and photoactivatable group.

[0085] In another exemplary embodiment, the reactive group or functional group may include an electrophilic and / or nucleophilic species, which in some embodiments may form a covalent bond therebetween. Exemplary electrophilic and nucleophilic functional groups include activated esters generally having the formula -COΩ, where Ω has a good leaving group (e.g., oxysuccinimidyl (-OC4H4O2), oxysulfosuccinimidyl (-OC4H3O2-SO3H), -1-oxybenzotriazolyl (-OC6HN3)), or an aryloxy group or an aryloxy group substituted one or more times with electron-withdrawing substituents such as nitro, fluoro, chloro, cyano, or trifluoromethyl, or a combination thereof, used to form an activated aryl ester, or an anhydride or mixed anhydride, -OCOR, activated by carbodiimide. a or -OCNR a NHR b carboxylic acid forming a and R b may be the same or different, C1-C6 alkyl, C rThe acyl azide may be a C6 perfluoroalkyl, or a C1-C6 alkoxy), or may include cyclohexyl, 3-dimethylaminopropyl, acyl halide groups, acyl nitriles, aldehydes, alkyl halides, anhydrides, aryl halides, aziridines, diazoalkanes, haloacetamides, halotriazines, isocyanates, isothiocyanates, maleimides, phosphoramidites, sulfonyl halides, sulfide groups, disulfide groups, epoxide groups, and episulfide groups, thioester groups, activated alcohol groups, phosphate groups, phosphate ester groups, and photoactivatable groups. Acyl azides can also rearrange to isocyanates.

[0086] In some embodiments, the reactive group further comprises a linker L in addition to the reactive functional group. The linker can be used to covalently bond the reactive functional group. When present, the linker is a single covalent bond or a series of stable bonds. The reactive functional group moiety can be directly bonded (when the linker is a single bond) or attached to a solid support, moiety, or small molecule through a series of stable bonds. When the linker is a series of stable covalent bonds, the linker typically contains several non-hydrogen atoms selected from the group consisting of C, N, O, S, Si, B, and P. Furthermore, the covalent bond can include a platinum atom, for example, as described in U.S. Pat. No. 5,714,327. When the linker is not a single covalent bond, it can optionally be any combination of stable chemical bonds, including single, double, triple, or aromatic carbon-carbon bonds, as well as carbon-nitrogen bonds, nitrogen-nitrogen bonds, carbon-oxygen bonds, sulfur-sulfur bonds, carbon-sulfur bonds, phosphorus-oxygen bonds, phosphorus-nitrogen bonds, and nitrogen-platinum bonds. In exemplary embodiments, the linker contains less than 15 non-hydrogen atoms and is composed of a combination of ether, thioether, thiourea, amine, ester, carboxamide, sulfonamide, hydrazide bonds, and aromatic or heteroaromatic bonds. Typically, the linker is a single covalent bond or a combination of a single carbon-carbon bond and a carboxamide, sulfonamide, or thioether bond. The following moieties may be found in the linker: ether, thioether, carboxamide, thiourea, sulfonamide, urea, urethane, hydrazine, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl, and amine moieties. Examples of L include substituted or unsubstituted polymethylene, arylene, alkylarylene, arylenealkyl, or arylthio.

[0087] Any combination of linkers can be used to connect functional groups or reactive groups.When the reactive group is maleimide or haloacetamide, the resulting compound is particularly useful for conjugation to thiol-containing substances.When the reactive group is hydrazide, the resulting compound is particularly useful for conjugation to periodate-oxidized carbohydrates and glycoproteins.When the reactive group is silyl halide, the resulting compound is particularly useful for conjugation to silica surfaces, especially when the silica surface is subsequently incorporated into an optical fiber probe used for remote ion detection or quantification.

[0088] In some non-limiting exemplary embodiments of the compositions of the present disclosure, a first size-exclusion carrier is conjugated to a first moiety, e.g., a first moiety comprising an amine-containing polymer, and a second size-exclusion carrier is conjugated to a second moiety, e.g., a second moiety comprising dextran.

[0089] In some other non-limiting exemplary embodiments of the compositions of the present disclosure, a first size-exclusion carrier is bound to a first moiety comprising, for example, poly(ethylene glycol) diamine, polyethylene diamine, linear polyethyleneimine, or branched polyethyleneimine, and a second size-exclusion carrier is bound to a second moiety comprising, for example, dextran.

[0090] In some other non-limiting exemplary embodiments of the compositions of the present disclosure, a first size-exclusion carrier is coupled to a first moiety comprising diethylenediamine, and a second size-exclusion carrier is coupled to a second moiety, the second moiety comprising, for example, dextran.

[0091] In some non-limiting exemplary embodiments of the compositions of the present disclosure, a first size-exclusion carrier is coupled to a first moiety, e.g., a first moiety comprising an amine-containing polymer, and a second size-exclusion carrier is coupled to a second moiety, e.g., a second moiety comprising a polyethylene glycol polymer.

[0092] Apparatus and devices: In some embodiments, the present disclosure provides an apparatus and / or device and / or system for removing one or more small molecules from a sample, the apparatus and / or device and / or system including: a) a container containing at least one size-exclusion carrier and at least one moiety capable of binding one or more small molecules; and b) a receptacle located below the container. In some embodiments of the device, apparatus, or system of the present disclosure, the receptacle is attached to a column. In some embodiments, the receptacle is removable from the column. The contents of the receptacle can be removed by a user. In some embodiments, the receptacle of the device collects a sample containing substantially reduced small molecules. In some embodiments, the receptacle of the device collects a sample free of small molecules.

[0093] Some embodiments of the presently disclosed devices, apparatus, or systems are configured to be operable to undergo gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, and combinations thereof. Structures that allow for the application of such pressures or forces include, but are not limited to, syringes that can be pulled to create positive pressure, vacuum frits to generate negative pressure, tubes or containers that are compatible with commercially available centrifuges or spinning devices.

[0094] The apparatus, device or system of the present disclosure is operable to separate, reduce the amount of or remove one or more small molecules by applying a sample to the device once and subjecting the device, apparatus or system of the present disclosure to one or more forces, such as vacuum, gravity, negative pressure or positive pressure applied to the sample in the container.

[0095] In some embodiments of the disclosed devices, apparatus, or systems, the container is a columnar container, a tube, a multi-well tube, a multi-well plate, or a multi-well filter plate. Exemplary containers include, but are not limited to, a test tube, a spin column, a multi-well plate, a multi-well filter plate, a microwell plate, or a microwell filter plate.

[0096] FIG. 3 illustrates a non-limiting three-dimensional (3D) view of an exemplary apparatus / device or system 100 according to one embodiment of the present disclosure, including a vessel 60 (such as a cylindrical tube, test tube, or spin column) having a filter, mesh, or porous surface area (not shown) at the vessel's bottom end. The vessel 60 may also include one or more frits (not shown). The vessel 60 contains or includes an exemplary composition 30 (at least one size-exclusion carrier and at least one moiety capable of binding one or more small molecules), an optional lid 60′ that can be used to secure the vessel 60 to the top. A receptacle 70 is positioned below the vessel 60 and is adaptable or configured to receive eluate or flow-through from the vessel through its bottom end. The receptacle 70 can be removed from the vessel 60 so a user can collect the flow-through or eluate. In some embodiments, the receptacle 60 has a twist-off tab configuration for removal. In other embodiments, the receptacle 70 may be attached to the container 60 by grooves or threads that may be attached and removed by manual or mechanical means, such as by attachment with a complementary fit that may be turned, twisted, or pulled apart.

[0097] 4A and 4B illustrate non-limiting three-dimensional (3D) views of an exemplary apparatus / device or system 100' according to one embodiment of the present disclosure, including a multi-well container 80 disposed therein, with example compositions 30 (at least one size-exclusion carrier and at least one moiety capable of binding one or more small molecules) disposed within each well, and an optional lid 80' for the container, which may be foil, clear wrap, a tear-off seal, and / or any type of removable / demountable lid.

[0098] The multiwell container 80 may be a multiwell plate, a multiwell plate filter, a microplate, or a microtiter plate, including a flat plate with multiple wells, each used as a small test tube or container. Multiwell plates come in a variety of formats for high-throughput applications and can typically have 6, 12, 24, 48, 96, 384, 1536, 3456, 9600, or more wells arranged in a rectangular matrix or array.

[0099] The multi-well vessel 80 may have a receptacle 70 located below the vessel that is adaptable or configured to receive eluate or flow-through from the vessel. In a multi-well filter plate, the vessel 80 may have a mesh, filter, flow-through, or other type of porous bottom that allows the flow-through or eluate to enter the receptacle 70 (not shown).

[0100] In some embodiments, such a receptacle 70 is a multi-well tray for collecting eluate or flow-through (see, e.g., FIG. 4A). The receptacle 70 is removable, and the eluate may be collected from the receptacle 70 by a user (see FIGS. 4A and 4B). In some embodiments, the receptacle 70 is a wash plate or a collection plate.

[0101] Although Figures 3, 4A and 4B merely illustrate exemplary devices and this specification uses these embodiments for illustrative purposes, other embodiments of the apparatus can be readily made by one skilled in the art by modifying the descriptions herein.

[0102] The one or more small molecules that may be removed or extracted by the device, apparatus, or system of the present disclosure may be or include dyes, dye derivatives, biotin, biotin derivatives, crosslinkers, reducing agents, labels, nanoparticles, radioligands, mass tags, unreacted molecules, and combinations thereof, intermediates and derivatives thereof.

[0103] Where the present disclosure has a molecular weight range of less than 2000 Da, small molecules may be removed by the device / apparatus or system, including molecular weight ranges of approximately 100-200 Da, 200-300 Da, 300-400 Da, 400-500 Da, 500-600 Da, 600-700 Da, 700-800 Da, 800-900 Da, 900-1000 Da, 1000-1100 Da, 1100-1200 Da, 1200-1300 Da, 1300-1400 Da, 1400-1500 Da, 1500-1600 Da, 1600-1700 Da, 1700-1800 Da, 1800-1900 Da, and less than 1900-2000 Da. In some embodiments, the present disclosure provides a method for producing a 50 Da, 100 Da, 150 Da, 200 Da, 250 Da, 300 Da, 350 Da, 400 Da, 450 Da, 500 Da, 550 Da, 600 Da, 650 Da, 700 Da, 750 Da, 800 Da, 850 Da, 900 Da, 950 Da, 1000 Da, 1050 Da, 1100 Da, 1150 Da, 1200 Da, 1250 Da, 1300 Da, 1400 Da, 1500 Da, 1600 Da, 1700 Da, 1800 Da, 1900 Da, 2100 Da, 2200 Da, 2300 Da, 2400 Da, 2500 Da, 2600 Da, 2700 Da, 2800 Da, 2900 Da, 3000 Da, 3100 Da, 3200 Da, 3300 Da, 3400 Da, 3500 Da, 3600 Da, 3700 Da, 3800 Da, 3900 Da, 4100 Da, 4200 Da, 4300 Da, 4400 Da, 450 Da, 4600 Da, 4700 Da, 4800 Da, 4900 Da, 5000 Da, 5100 Da, 5200 Da, 5300 Da, 5400 Da, 5500 Da, 6000 Da, 650 Da, 7000 Da, 750 Da, 800 Da, 850 Da, 900 Da, 950 Da, 1000 Da, Small molecules may be removed by the device / apparatus or system if they have a molecular weight range of less than or equal to 1300 Da, 1350 Da, 1400 Da, 1450 Da, 1500 Da, 1550 Da, 1600 Da, 1650 Da, 1700 Da, 1750 Da, 1800 Da, 1850 Da, 1900 Da, 1950 Da, 1975 Da to about 2000 Da.

[0104] The systems, apparatus and devices of the present disclosure, in embodiments, include a container containing one or more compositions of the present disclosure, as described in detail in the sections above and below.

[0105] One or more advantages of the systems, apparatus, and devices of the present disclosure include one or more of the following: economical, simple and easy to use, provide faster time to results, adaptable as single-use disposable units, amenable to automated and robotic sample preparation systems, usable for high-throughput sample preparation in multi-well vessel formats. Reducing the amount of small molecules from a sample using the apparatus, devices, and systems provided herein provides rapid and superior quality of biomolecules and their derivatives that can be used in downstream applications.

[0106] system In some embodiments, the present disclosure provides a system for removing one or more small molecules from a sample, the system comprising: a) a container comprising a size-exclusion carrier and at least one moiety capable of binding at least one or more small molecules; and b) a receptacle located below the container. In some embodiments, the system further comprises means for subjecting the container and the container to gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, and combinations thereof.

[0107] In some embodiments, the systems of the present disclosure may include the device 100 or 100'' illustrated above, which may be configured to be housed in a centrifuge tube or any other equivalent rotating apparatus. In some embodiments, the systems of the present disclosure may include the device 100 or 100'' illustrated above, which may be configured to receive negative pressure (such as a vacuum) or positive pressure (such as a syringe, pipette, etc.).

[0108] The systems of the present disclosure (not shown) can be fully automated or can be manually operated systems, in some embodiments the systems can be partially manually operated and partially automated.

[0109] The system may also include a computer system including a CPU, hardware and / or software elements, which may be physically internal or external and operatively linked to the hardware / software elements. The computer system may be operable to control various components of device 100 or 100'', such as controlling robotics for collecting eluate and analyzing the eluate.

[0110] The systems of the present disclosure may also optionally include one or more devices operable to further process the eluted biomolecules, such as processing the eluted derivatized proteins, such as conjugated antibodies or tagged proteins, for fluorescent detection or immunoassays. In some embodiments, the systems may include an imager, a protein or nucleic acid detector, or a sequencer.

[0111] A computer system may be operable to control one or more components of the disclosed system. In some embodiments, as described above, the computer system and / or its components may be physically present within device 100 or 100" or may be external. The computer system may include a central processing unit, hardware and software elements operable to control and direct the automated steps of sample processing (by device 100 or 100" and other components of the system) and / or data processing of data acquired by processing the samples and / or by downstream data processing of the data. Accordingly, a computer system, as used herein, may include a data analysis and control system, a data transfer system such as a read / write CD ROM drive or DVD drive, at least one USB port, and / or at least one Ethernet port. In some embodiments, the computer system may include preloaded software and / or application specific integrated circuits (ASICS) that may enable control of device 100, 100" and / or other components of the system, including control of processing and analysis, and / or control of display and / or export of results.

[0112] The system may also include additional devices or components such as a power supply, a display unit such as a monitor operable to display sample processing and / or monitor extraction of biomolecules from the sample, a spectrophotometer, a device for measuring nucleic acid extraction; a device for further processing the extracted biomolecules for further analysis, a printer, etc. The system of the present disclosure may be configured to fit on a laboratory benchtop.

[0113] method In some embodiments, the present disclosure describes a method for separating biomolecules from one or more small molecules, comprising: a) applying a sample containing biomolecules to a container comprising a size-exclusion carrier and at least one moiety capable of binding to one or more small molecules; and b) subjecting the container to gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, or a combination thereof, wherein biomolecules in the sample are excluded by the size-exclusion carrier and collected as flow-through, and one or more small molecules bind to the at least one moiety and are thereby separated from the biomolecules.

[0114] In some embodiments of the disclosed methods, separation of at least one small molecule from the remainder of the sample is performed in one step. In some embodiments of the disclosed methods, the flow-through is collected in a receptacle located below the container. In some embodiments, the small molecule may constitute an impurity or contaminant to the sample.

[0115] Various samples that can be tested by the methods of the present disclosure can be any type of biological or clinical sample that may have biomolecules or derivatives thereof from which small molecules must be separated or removed. Some exemplary, non-limiting samples include samples with protein-dye conjugates, biotinylated protein samples, proteins containing reducing agents such as DTT or TCEP crosslinked proteins, and protein samples containing crosslinkers. Dyes that are suitable for use are known to those of skill in the art and include pyrenes, coumarins, cyanines, benzofurans, quinolines, quinazolinones, indoles, benzazoles, borapolyazaindacenes, and xanthenes, including fluoresceins, rhodamines, and rhodols, as well as those described in RICHARD P. HAUGLAND, MOLECULAR PROBES HANDBOOK OF FLUORESCENT PROBES AND RESEARCH CHEMICALS (11 th Other dyes include, but are not limited to, those described in the "Pigment Coloring Book" (Pigment Coloring Book, January 2010).

[0116] The disclosed methods may advantageously reduce the time required to process a sample to reduce the amount of small molecules from the sample.

[0117] kit The present disclosure also describes kits for practicing the methods discussed herein and / or kits containing the compositions and / or kits containing the apparatus / devices discussed herein.

[0118] In some embodiments, the present disclosure describes a kit for separating a biomolecule from one or more small molecules, the kit comprising a device, the device comprising: a) a container comprising at least one size exclusion resin and at least one moiety capable of binding to and capturing at least one small molecule; and b) a receptacle located below the container, wherein the device is configured to be operatively subjected to gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, and combinations thereof.

[0119] In some embodiments, kits of the present disclosure comprise at least two or more moieties capable of binding to one or more small molecules.

[0120] In some embodiments of the kit of the present disclosure, the device is a spin column, a multi-well filter plate, or a multi-well plate. The kit may further include one or more buffers packaged in one or more separate containers or contained in the first container.

[0121] Kits of the present disclosure may also include one or more reagents such as one or more wash buffers, elution buffers, filter membranes and / or additional spin columns or multi-well plates.

[0122] The reagents and components of the kit may be contained in one or more suitable container means. The container means may generally include at least one vial, test tube, flask, bottle, syringe, or other container means into which the components are placed, preferably suitably aliquoted. When multiple components are present in the kit, they may be packaged together if suitable, or the kit will typically include second, third, or other additional containers into which additional components may be individually placed. However, in some embodiments, a particular combination of components may be packaged together to be contained in a single container means. The kit may also include means for storing the reagent containers in close confinement for commercial sale. Such containers may include injection- or blow-molded plastic containers into which the desired vials are retained.

[0123] In some embodiments, the devices of the disclosed kits may be pre-filled with one or more reagents for processing the sample and suitably aliquoted into the appropriate chambers. The kit or its container may have a seal to keep the internal compartment and any contents therein sterile and hermetic.

[0124] Some components of the kit may be provided in one or more liquid solutions. The liquid solutions may be non-aqueous, aqueous, or sterile. The components of the kit may also be provided as dry powders. When reagents and / or components are provided as dry powders, the powders may be reconstituted by adding a suitable solvent. It is contemplated that a suitable solvent may also be provided in a separate container means. The kit may also include container means for containing a sterile, pharmaceutically acceptable buffer and / or other diluent.

[0125] Kits of the present disclosure may also include instructions for using the kit components, and may also include instructions for the use of other reagents not included in the kit. The instructions may include variations that may be performed. [Example]

[0126] Aspects of the present teachings may be better understood in light of the following examples, which should not be construed as limiting the scope of the present teachings in any way.

[0127] Example 1. Preparation and testing of compositions Compositions for separating or extracting one or more small molecules from a sample comprising at least one size-exclusion carrier and at least one moiety capable of binding one or more small molecules have been prepared and tested.

[0128] In some embodiments, exemplary size-exclusion supports were modified with moieties that contain functional groups that can bind small molecules, either through charge interactions, hydrophobic interactions, or any other interaction, thereby removing these small molecules from a sample, while allowing larger biomolecules in the sample to be excluded and recovered.

[0129] In this and the following examples, compositions for removing four exemplary types of small molecules were prepared and tested for their ability to remove small molecules, including dyes (within a molecular weight range of about 700 Da to 1100 Da), biotin and its derivatives (within a molecular weight range of about 300 Da to 1000 Da), reducing agents (within a molecular weight range of about 150 Da to 300 Da), and cross-linkers (within a molecular weight range of about 300 to 600 Da). While these exemplary small molecules and the listed molecular weight ranges were used in the experimental demonstrations, those skilled in the art will understand that the present embodiments are not limited to any of these small molecules or molecular weight ranges, and that the teachings herein will enable those skilled in the art to prepare and use compositions and devices for removing a variety of small molecule types and molecular weight ranges.

[0130] The following moieties were variously immobilized onto size-exclusion support resins: 1. dextran with molecular weights ranging from 6 kDa to 2800 kDa), 2. polyethyleneimine (PEI) (linear and branched), and 3. diethylenediamine (DEA).

[0131] Example 1A: Preparation and Testing of Chemical 1 Chemical 1: Immobilization on branched polyethyleneimine moieties of size-exclusion supports: Two examples of size-exclusion supports, including Thermo Scientific's Zeba 40K spin desalting column and Zeba 7K spin desalting column, containing hydroxyethyl cellulose resin with 7K and 40K size exclusion ranges, were modified as described below. Vicinal diols located on these size-exclusion support columns were oxidized with periodate to generate aldehyde groups. Using Schiff base chemistry, polyethyleneimine and diethylenediamine bearing primary amines were reacted with the generated aldehydes. Polyethyleneimine and diethylenediamine were prepared in PBS, the pH adjusted to 8.0–8.5, and reacted with the oxidized Zeba column. These compositions are subsequently referred to as Zeba 7K-PEI (polyethyleneimine) and Zeba 40K-PEI (polyethyleneimine).

[0132] The same chemical modification was performed on an agarose resin without size exclusion properties (GE Sepharose Fast flow 4 (FF4) resin). Vicinal diols on the agarose resin were oxidized with periodate to generate aldehyde groups. Using Schiff base chemistry, polyethyleneimine and diethylenediamine, which have primary amines, were reacted with the generated aldehydes. Polyethyleneimine and diethylenediamine were prepared in PBS, the pH adjusted to 8.0–8.5, and reacted with the oxidized agarose resin. This resulted in the formation of agarose-PEI (polyethyleneimine), which will be described in a later experiment.

[0133] The following experimental steps were performed using a chemically modified size-exclusion support (e.g., the Zeba column example above) and a non-size-exclusion support (e.g., the Sepharose resin example above): 1. A bed volume of 0.5 mL of chemically modified support was added to each spin column. 2. The spin columns containing the various chemically modified supports were spun at 1000 x g for 2 minutes to remove the storage solution. 3.a) A sample containing an antibody-conjugated dye was added at 100 μL onto the chemically modified support in the spin column. The column was spun at 1000 x g for 2 minutes, and the flow-through was collected.

[0134] The results of these experiments are illustrated in Figure 5, which shows the removal of an exemplary small molecule (free dye) using two exemplary compositions in a device of the present disclosure using a method according to one embodiment of the present disclosure. Different example compositions of the present disclosure, including size-exclusion carriers (at least two types of hydroxyethyl cellulose carriers with size-exclusion ranges of 7K and 40K each individually bound with a combination of moieties including polyethyleneimine (as an exemplary first moiety) and diethylenediamine (as an exemplary second moiety)), were used to remove small molecules, embodied herein by free dye (DyLight™ 650). The comparative efficiency of a simple detergent removal resin was also tested under similar conditions.

[0135] The various lanes of the gel in Figure 5 were loaded as follows: Lane 1 - GAM (GoatAntiMouse) DyLight™ 650 conjugate (uncleaned - control), Lane 2 - detergent removal resin (Pierce™ detergent removal resin, HiPPR™ detergent removal spin column kit), Lane 3 - agarose-PEI (polyethyleneimine), Lane 4 - Zeba7K-PEI (polyethyleneimine), Lane 5 - Zeba40K-PEI (polyethyleneimine).

[0136] The two bands in the boxes in Figure 5 represent the recovered protein in each lane, i.e., GoatAntiMouse DyLight™ 650 conjugate protein (GAM DyLight™ 650 conjugate), and the bottom band represents the free dye DyLight™ 650 remaining in the sample. Free or unreacted dye 650 was retained on the column and eluted after protein recovery. Lane 1 is the uncleaned GAM 650 conjugate. The term "uncleaned" is used here to represent GAM DyLight™ 650 conjugate that has not been passed through any resin or carrier. "Uncleaned" is a control run on the gel to demonstrate what a sample containing free dye that has not been "removed" by the disclosed compositions, devices, and methods would look like on the gel. Lane 2 shows GAM650-conjugated protein passed through an exemplary simple detergent removal resin (Pierce™ Detergent Removal Resin, HiPPR™ Detergent Removal Spin Column Kit) to test whether this type of resin can remove small molecules (such as free dye). The presence of a bottom band indicates that free dye is not completely or efficiently removed by this resin compared to the other lanes (especially compared to lanes 4 and 5). Lane 3 shows that the GAM650-conjugated protein is somewhat separated from free dye by PEI immobilized on the agarose resin. However, lane 3 shows relatively low protein recovery and insufficient free dye removal compared to lanes 4 and 5. Lanes 4 and 5 show relatively good protein recovery compared to lanes 1, 2, and 3. The bottom band, showing the complete absence of free dye in lanes 4 and 5, indicates that free dye is efficiently removed by the PEI-modified size-exclusion resins (7K and 40K Zeba resins). However, recovery of the GAM 650 conjugate with non-size-exclusion agarose resin is poor compared to recovery with size-exclusion resins such as the 7K and 40K Zeba resins in lanes 4 and 5.Thus, lanes 4 and 5 using the compositions, devices, and methods of the present disclosure demonstrate optimal removal of small molecules as shown here compared to other lanes, due to the absence of free dye and efficient recovery of conjugated proteins (large biomolecules). Quantitative data for other dyes is shown in the Examples below.

[0137] Thus, at least two compositions of the present disclosure were analyzed in this experiment: 1. a 7K size-exclusion hydroxyethylcellulose carrier bound to a moiety combination comprising polyethyleneimine (as an exemplary first moiety) and diethylenediamine (as an exemplary second moiety); and 2) a 40K size-exclusion hydroxyethylcellulose carrier bound to a moiety combination comprising polyethyleneimine (as an exemplary first moiety) and diethylenediamine (as an exemplary second moiety). The two compositions of the present disclosure were compared and contrasted with the performance of a non-size-exclusion carrier chemically modified in the same manner as the compositions of the present disclosure (i.e., an agarose carrier bound to a moiety combination comprising polyethyleneimine (as an exemplary first moiety) and diethylenediamine (as an exemplary second moiety), as well as a detergent removal resin and an "uncleaned" control). As shown in the above experiment and results (and in Figure 5), neither the modified non-size-exclusion carrier nor the detergent removal resin were able to remove small molecules as efficiently as the composition of the present disclosure comprising the modified size-exclusion carrier.

[0138] Example 1B: Preparation of Chemical Substance 2 Chemical 2: Immobilization of Size-Exclusion Supports with Dextran Moieties. In this example, 7K and 40K hydroxyethyl cellulose resins (Zeba™ Spin Desalting Columns, 40K, and Zeba™ Spin Desalting Columns, 7K) were attached to dextran moieties to form additional compositions of the present disclosure. Different MW dextrans (ranging from 6K Daltons to 2.8 million Daltons) were immobilized on the 7K and 40K resins.

[0139] First, dextran with molecular weights ranging from 1,500,000 Da to 2,800,000 Da was immobilized onto the resin as described below. Vicinal diols on the hydroxycellulose size-exclusion support were periodate-oxidized to generate aldehyde groups. Ethylenediamine (EDA) or 1,5-diaminopentane (PDA) was reacted with the generated aldehydes using Schiff base chemistry. This generated terminal amine groups on both the 7K and 40K size-exclusion support. Next, the dextran solution was periodate-oxidized using sodium metaperiodate to generate aldehyde groups. The aldehyde groups generated on the dextran were then reacted with the terminal amines to generate dextran immobilized on the 7K and 40K resins.

[0140] Similar compositions and chemical modifications were also prepared on agarose, a non-size-exclusion support, for comparative analysis. As noted in the previous section, agarose does not have size-exclusion properties. The chemical reactions are as follows: [ka]

[0141] Example 1C: Preparation of Chemical Substance 3 Chemical 3: Immobilization of size-exclusion supports with branched polyethylene glycol amine moieties: Compositions containing size-exclusion supports (Zeba, 7K and 40K, Thermo Scientific) bearing poly(ethylene glycol) bis(amine) were prepared as follows: Poly(ethylene glycol) bis(amine) moieties of different molecular weights (2K Daltons to 20K Daltons) were immobilized to size-exclusion supports (7K and 40K resins) using Schiff base chemistry as described in the previous section.

[0142] For comparative analysis, a similar chemical modification was also performed on a non-size-exclusion agarose support (Agarose, GE Healthcare). The chemical reaction is illustrated below. [ka]

[0143] Example 1D: Testing of Chemicals 2 and 3: Removal of Free Dye Small Molecules by Chemicals 2 and 3 in a Spin Column Device The compositions of Chemicals 2 and 3 above were tested for removal of small molecules.

[0144] All experiments for removing small molecules (unless specifically noted in this and other examples as using other methods or devices) were performed using a 0.5 mL resin bed volume (of the various chemistries variously described above) assembled in a 0.8 mL spin column to create a device according to a non-limiting embodiment of the present disclosure. The spin column was spun at 1000 x g for 2 minutes to remove the storage solution. The spin column was then placed into a clean 2 mL centrifuge tube. A 100 μL sample volume was added to the center of the resin, the column was spun at 1000 x g for 2 minutes, and the flow-through was collected in a 2 mL tube. The results of these experiments are depicted graphically in Figure 6.

[0145] Figure 6 illustrates the removal of another exemplary small molecule, free dye, DyLight™ 550 NHS Ester, using different carriers of the present disclosure, including 20k PEG-diamine Zeba 7k, dextran-PDA Zeba 7k (PDA refers to 1,5-diaminopentane), and controls including Zeba 7k (unmodified) and the starting sample (control), as well as a comparison with another chemistry including Zeba 7k and dextran resin (crosslinked together). This experiment was performed without protein to demonstrate the ability of compositions of the present disclosure to bind small molecules, such as free dye (e.g., DyLight™), compared to unmodified size-exclusion resin (such as unmodified Zeba 7K resin in the lane).

[0146] DyLight™ 550 NHS-Ester was prepared at 1.3 mg / mL in borate buffer (this corresponds to a 20 molar excess of dye per 10 mg of GAM protein). Five hundred microliters of the different carriers and controls of the present disclosure were assembled into 0.8 mL spin columns. 100 μL of 1.3 mg / mL DyLight™ 550 NHS-Ester was added to the resin. The spin columns were spun at 1000 × g in a centrifuge for 2 minutes. The flow-through was collected. 10 μL of the flow-through was added to 90 μL of sample buffer. 10 μL of this was then added per well to a 4-20% Tris Glycine SDS gel. The gel was run for 40 minutes and then imaged using an iBright imager (Thermo Fisher Scientific). The lanes in Figure 6 correspond to the following support compositions used to remove free dye: lane 1—20k PEG-diamine Zeba 7k, lane 2—dextran-PDAZeba 7k, lane 3—Zeba 7k (unmodified), lane 4—Zeba 7k and dextran resin (crosslinked together), lane 5—starting sample or positive control (20 molar excess of DyLight™ 550 NHS-Ester in borate buffer).

[0147] Lane 1 in Figure 6 illustrates data for small molecule removal using PEG-diamine immobilized on 7K Zeba resin. This chemistry was not successful in removing free dye. Lane 2 illustrates data for dextran-PDA immobilized on 7K size-exclusion support resin, which removed 100% of the free dye. Lane 3, which is unmodified 7K Zeba resin (i.e., size-exclusion resin only, no added moieties—no surface chemistry), was not successful in removing free dye. Lane 4 corresponds to a resin prepared with a different chemistry for comparison with this composition. The resin in lane 4 was prepared by crosslinking hydroxyethyl cellulose and dextran using a crosslinker, as opposed to immobilizing dextran on Zeba resin. This crosslinking chemistry was less effective than the chemistry in lane 2, where dextran was immobilized on the size-exclusion support via the reductive amination method described above. As can be seen in lane 2, the free dye was completely removed, as illustrated by the absence of a free dye band, while a free dye band was present in lane 4, indicating that the free dye was not removed by the cross-linked resin. Lane 5 shows an "uncleaned" sample that was run as described in the previous section. Here, 1.3 mg / mL of DyLight™ 550 NHS-Ester was not run through the resin. This 1.3 mg / mL solution was diluted 1:10 in sample buffer as described above and loaded onto the gel.

[0148] Example 1E: Testing of Chemicals 2 and 3: Removal of Reducing Agent Small Molecules Using Chemicals 2 and 3 Another composition of the present disclosure, produced as described in Chemical 3 and containing a single-moiety PEG (polyethylene glycol) diamine immobilized on a size-exclusion support (7K Zeba, Thermo Scientific), was tested for its ability to remove small molecules that function as reducing agents as follows: 714 μl of 70% support resin slurry was pipetted into a spin column placed in a collection receptacle tube. The spin column was spun at 1000 × g for 2 minutes to remove the storage solution. The spin column was then placed into a clean 2 mL centrifuge tube. A 100 μL sample volume containing the reducing agent tris(2-carboxyethyl)phosphine (TCEP) at a concentration of 50 mM in PBS was added to the center of the spin column containing the above composition, spun at 1000 × g for 2 minutes, and the flow-through was collected in a 2 mL tube. The removal of TECPs from the sample was tested by Ellmans Assay. This assay was performed by adding the following to a 96-well plate: a) 250 μl of Ellmans buffer; b) 10 μl of Ellmans reagent (4 mg / ml). c) 50 μl of sample (diluted 1:10), then measure the amount of TCEP by reading the sample at 450 nm on a colorimeter (Multiskan, Thermo Scientific). The amount of TCEP in the sample is proportional to the intensity of the color indicated by the reading at 450 nm. Thus, a higher reading at 450 nm corresponds to a higher amount of TCEP present in the sample. The results of these experiments are shown in Figure 7. A lower value at 450 nm indicates efficient removal of TCEP.

[0149] FIG. 7 shows the removal of an exemplary small molecule, a reducing agent (TCEP), using compositions, devices, and methods according to one embodiment of the present disclosure, comparing them to a control containing unmodified Zeba 7K. As shown in FIG. 7, the first bar corresponds to PEG-diamine immobilized on a size-exclusion support resin, exemplified by Zeba 7K, and shows 97% removal of TCEP added to the resin at 50 mM. The second bar corresponds to dextran-PDA immobilized on a size-exclusion support resin, exemplified by Zeba 7K, and shows 80% removal of TCEP. In contrast, the third bar in FIG. 7 shows the results of passing a 50 mM TCEP sample through a chemically unmodified size-exclusion support resin (exemplified by unmodified Zeba 7K resin), showing 41% removal of TCEP. The fourth bar shows the effect of a different chemistry, including 7K Zeba resin crosslinked to dextran, showing only 12% removal of TCEP. Thus, compositions of the present disclosure made according to Chemistry 2 and Chemistry 3 exhibit significantly higher removal of the small molecule reducing agent TCEP compared to the other compositions.

[0150] Example 2: Blend Composition and Small Molecule Removal in Spin Column and Multiwell Formats Data from the experiments illustrated in Figures 5, 6, and 7 demonstrate that a size-exclusion support resin alone (i.e., Zeba 7K without any associated moieties or chemistries) is unable to remove small molecules, including, for example, dyes or reducing agents such as TCEP. Compositions of the present disclosure comprising a size-exclusion resin and dextran were able to remove both types of small molecules, including dyes and reducing agents. For example, the data in Figures 5 and 6 demonstrate that compositions of the present disclosure comprising dextran immobilized on a size-exclusion support (Zeba 7K and 40K in Figure 5 and Zeba 7K in Figure 6) remove free, unreacted dyes (Dye 650, NHS 550), and dextran PDA in Figure 7 removes the reducing agent TCEP. However, some compositions of the present disclosure, including, for example, PEG-diamine moieties immobilized on a size-exclusion support (Zeba 7K), enabled the removal of significant amounts of the small molecule reducing agent TCEP (see Figures 7 and 13) and DTT (see Figure 19), but were unable to remove small dyes (see Figure 6, lane 1).

[0151] Therefore, the inventors have created compositions comprising blends of various compositions described herein to produce compositions capable of removing several types of small molecules. Some exemplary blend compositions of the present disclosure are shown in Table 1. [Table 1]

[0152] Blends 1-5, as described in Table 1, containing compositions of dextran immobilized on a size-exclusion 7K resin and compositions of PEG diamine immobilized on a size-exclusion 7K resin, were prepared with various ratios of each composition as described in columns 2 and 3 of Table 1.

[0153] The blends in Table 1, made in a 1:1 ratio, were tested for their ability to remove different classes of small molecules and compared to similar tests performed with corresponding controls of unmodified size exclusion resin (7K Zeba resin) and controls of uncleaned conjugated protein.

[0154] To test the performance of the compositions in the disclosed devices, the blend compositions were incorporated into spin columns of various sizes (0.8 mL, 2 mL, 5 mL, and 10 mL) and also incorporated onto a 96-well filter plate. The spin columns or multiwell plates were spun in a centrifuge at 1000 x g for 2 minutes, and the storage buffer was removed. An appropriate amount of sample containing a small molecule was added. The columns or multiwell plates were again spun in a centrifuge at 1000 x g for 2 minutes, and the eluate was collected in the flow-through. The data are shown in Figures 8, 9, and 10, and correspond to experiments performed in the spin column format.

[0155] For Figure 8, a sample volume of 700 μL of goat anti-mouse IgG conjugated with a 10 molar excess of DyLight™ 550 was applied to the center of the spin column, with the composition corresponding to each lane, as shown below. Free dye removal was assessed in the flow-through by SDS-PAGE, imaging the gel on an iBright imager, and then quantification of dye removal with iBright analysis software. The modified 7k 1:1 blend sample (lanes 1-2) had greater than 99% dye removal, and the unmodified 7k Zeba resin (lane 3) had 20% dye removal compared to the 10 mg / ml "uncleaned" starting sample (lane 4) with goat anti-mouse IgG containing a 10 molar excess of DyLight™ 550 dye. Percent removal of small molecules is calculated relative to that in the "uncleaned" control.

[0156] Figure 8 shows the small molecule dye removal of DyLight™ 550 from protein complexes of DyLight™ 550 goat anti-mouse IgG using a 1:1 ratio of the exemplary blend compositions in Table 1. Lane 1 has data for dye removal using a 1:1 dextran-PDA blend, lane 2 has data for a dye-removing 1:1 dextran-EDA (ethylenediamine) blend, lane 3 has data for dye removal using unmodified 7KZeba size-exclusion resin, and lane 4 has data for an "uncleared" control of the dye DyLight™ 550 goat anti-mouse IgG. Figure 7 shows that the blends in lanes 1 and 2 are able to remove a significant amount of free dye compared to the control and lane 3. This is indicated in Figure 7 by the absence of a significant free dye band at the bottom of the gel.

[0157] In Figure 9, a 2 mL sample volume of goat anti-rabbit IgG conjugated with a 10 molar excess of Alexa Fluor™ 488 was applied to the center of a spin column containing a composition corresponding to that described below for each lane. The column was spun at 1000 x g in a centrifuge for 2 minutes, and the flow-through was collected. Free dye removal in the flow-through from each column was assessed by SDS-PAGE, imaging the gel on an iBright imager, and then quantifying dye removal with iBright analysis software. The modified 7k 1:1 blend sample (lanes 1-2) had greater than 99% dye removal compared to the "uncleaned" starting sample (lane 4) consisting of 10 mg / ml goat anti-rabbit IgG and 10 molar excess of Alexa Fluor™ 488 dye, while the unmodified 7k Zeba resin (lane 3) had 49% dye removal.

[0158] Figure 9 illustrates the small molecule dye removal of Alexa Fluor™ 488 from a protein conjugate of Alexa Fluor™ 488 goat anti-rabbit IgG using a 1:1 ratio of the exemplary blend compositions in Table 1. Lane 1 has data for dye removal using a 1:1 dextran-PDA blend, lane 2 has data for the dye-removed 1:1 dextran-EDA blend, lane 3 has data for dye removal using unmodified 7KZeba size-exclusion resin, and lane 4 has data for an "uncleaned" control of dye Alexa Fluor™ 488 goat anti-rabbit IgG. Figure 9 shows that the blends in lanes 1 and 2 remove a significant amount of free dye compared to the control in lane 4 and the unmodified resin in lane 3. This is illustrated by the absence of a significant lower free dye band.

[0159] In Figure 10, a 4 mL sample volume of goat anti-mouse IgG conjugated with a 10 molar excess of DyLight™ 650 was applied to the center of a pin column with the composition corresponding to each lane, as shown below. Free dye removal was assessed in the flow-through by SDS-PAGE, imaging the gel on an iBright imager, and then quantification of dye removal with iBright analysis software. The modified 7K 1:1 blend sample (lanes 1-2) showed greater than 99% dye removal compared to the "uncleaned" starting sample (lane 4) with 10 mg / ml goat anti-mouse IgG with a 10 molar excess of DyLight™ 550 dye, whereas the unmodified 7K Zeba resin (lane 3) showed only 22% dye removal.

[0160] Figure 10 shows the small molecule dye removal of DyLight™ 650 from a protein conjugate of DyLight™ 650 goat anti-mouse IgG using a 1:1 ratio of the exemplary blend compositions in Table 1, where lane 1 has data for dye removal using a 1:1 dextran-PDA blend, lane 2 has data for the dye-removing 1:1 dextran-EDA blend, lane 3 has data for dye removal using unmodified 7KZeba size-exclusion resin, and lane 4 has data for an "uncleared" control of the dye DyLight™ 650 goat anti-mouse IgG. Figure 10 shows that the blends in lanes 1 and 2 remove a significant amount of free dye, as indicated by the near absence of a free dye band at the bottom.

[0161] In Figures 8, 9 and 10, the removal of various dyes / small molecules is expressed as a % compared to their respective amounts in the "uncleaned" sample (lane 4 of each gel).

[0162] The blends in Table 1, made at a 1:1 ratio, were also tested for their ability to remove different classes of small molecules and compared with similar tests performed on the corresponding non-size-exclusion agarose-dextran and agarose-PEG diamine resins, also blended at a 1:1 ratio (referred to herein as FF4 blends in Figures 12 (lanes 5A and 5B), 13, 14, 15, and 16). A 0.5 ml bed volume of these compositions was incorporated into a spin column with a column volume of 0.8 ml to compare them with the compositions and devices of the present disclosure. The spin column was first spun in a centrifuge at 1000 x g for 2 minutes to remove the storage buffer. An appropriate amount of sample containing small molecules was added. The column was again spun in a centrifuge at 1000 x g for 2 minutes, and the eluate was collected in the flow-through. The data are shown, for example, in Figure 12 (lanes 5A and 5B), and Figures 13, 14, 15, and 16.

[0163] Example 3: Removal of free dye small molecules by blend compositions in a multi-well filter plate device The above blend compositions were tested for small molecule removal using a multi-well filter plate device format.

[0164] All experiments for removing small molecules were performed using a 0.5 mL resin bed of modified 7k 1:1 resin blend (of the different chemistries variously described above) assembled in a microwell / multiwell plate to create a device according to a non-limiting embodiment of the present disclosure. For these experiments, a 96-well multiwell plate containing the described chemistries was placed on top of a 96-well wash plate. This assembly was then placed in a 96-well plate carrier rotor and centrifuged at 1000 x g for 2 minutes to remove the storage buffer. The plate assembly was removed from the centrifuge, and the wash plate was discarded. The 96-well plate was then placed on top of a 96-well collection plate. Samples (20 μl, 50 μl, and 100 μl) were applied to the center of the resin bed in each well. The plate assembly was centrifuged at 1000 x g for 2 minutes to recover the samples. Free dye was removed and the antibody conjugate was recovered. Free dye removal was assessed by SDS-PAGE, imaging gels on an iBright imager, followed by quantification of dye removal with iBright analysis software. Results for multiwell plates are illustrated in Figure 11.

[0165] In Figure 11, lanes 1 and 2 correspond to 20 μl of goat anti-rabbit IgG Alexa Fluor™ 647 conjugate applied to the modified 7K 1:1 resin blend. Lanes 3 and 4 correspond to 50 μl of goat anti-rabbit IgG Alexa Fluor™ 647 conjugate applied to the modified 7K 1:1 resin blend. Lanes 5 and 6 correspond to 100 μl of goat anti-rabbit IgG Alexa Fluor™ 647 conjugate applied to the modified 7K 1:1 resin blend. Lane 7 corresponds to an "uncleaned" sample of goat anti-rabbit IgG Alexa Fluor™ 647 conjugate that was not applied to any resin blend. All samples (lanes 1-6) show greater than 99% dye removal compared to the "uncleaned" sample (lane 7) consisting of 10 mg / ml of goat anti-rabbit IgG conjugated with a 10 molar excess of Alexa Fluor™ 647 dye. Lanes 1-2 are the flow-through from a 20 µl sample applied to the resin bed, lanes 3 and 4 are the flow-through from a 50 µl sample applied to the resin bed, lanes 5 and 6 are the flow-through from a 100 µl sample, and lane 7.

[0166] Example 4: Blend composition for removing pigments without small molecules FIG. 12 illustrates data for the removal of an exemplary small molecule, two exemplary free dyes, fluorescein and Alexa Fluor™ 555, using blend compositions, devices, kits and methods according to one embodiment of the present disclosure.

[0167] Figure 12 The experimental procedure is as follows: Dye removal protocol: 1. Pipette 1 ml of 50% resin slurry into a spin column placed in a collection tube. 2. Spin out the liquid at 1000 x g for 2 minutes. 3. Replace the collection tube and add the antibody samples (GAR fluorescein conjugate and GAM Alexa 555 conjugate) to each spin column for each sample. 4. Centrifuge at 1000 x g for 2 minutes to remove free dye from the samples.

[0168] Evaluate dye removal in gels: 1. Prepare samples for running on gels by adding the following to a microcentrifuge tube: a) 20 μl 2x loading buffer with 50 mM DTT and b) 20 μl flow-through from the antibody cleanup from step 4 above. 2. Heat samples to 95°C for 8 minutes. 3. Cool samples on ice. 4. Load 10 μl of each sample into separate wells on the gel. 5. Run gel at 225V for 32 minutes. 6. Remove and rinse gel. 7. Image on an iBright imager with the appropriate fluorescence.

[0169] In FIG. 12, lanes 1-6 (A or B) contain the following blend compositions: lanes 1A and 1B contain 40K Zeba, an unmodified size-exclusion resin with a molecular weight cutoff of 40K; lanes 2A and 2B contain 7K Zeba, an unmodified size-exclusion support resin with a molecular weight cutoff of 7K; lanes 3A and 3B contain 40K Blend, a 1:1 blend of dextran-modified 40K resin and PEG diamine-modified 40K resin; lanes 4A and 4B contain 7K Blend, a 1:1 blend of dextran-modified 7K resin and PEG diamine-modified 7K resin; and lanes 5A and 5B contain Fast Flow, a non-size-exclusion resin blended in a 1:1 ratio containing dextran-modified FF4 and PEG diamine-modified FF4. Lanes A (lanes 1A-6A) contain GAR or goat anti-rabbit IgG-fluorescein conjugated proteins, and lanes B (lanes 1B-6B) contain GAM or goat anti-mouse IgG-Alexa Fluor™ 555-conjugated proteins.

[0170] Lanes 6A and 6B illustrate the "uncleaned" sample, showing two bands at the top corresponding to the reduced antibody band and the free dye band at the bottom of the gel (the free dye band in lane 6A corresponds to free fluorescein dye, and lane 6B corresponds to free Alexa Fluor™ 555 dye). In the treated samples (lanes 1A to 5A and 1B to 5B), the presence of the bottom dye bands indicates incomplete or failed removal of free dye (fluorescein and Alexa Fluor™ 555), as shown in lanes 1A, 1B, and 2A and 2B. The presence of the free fluorescein bands at the bottom in lanes 1A and 2A indicates poor or no removal of free fluorescein by the unmodified 40K and unmodified 7K Zeba resins, respectively. Similarly, the presence of free Alexa Fluor™ 555 bands at the bottom of lanes 1B and 2B indicates poor removal of free Alexa Fluor™ 555 dye by the unmodified 40K and unmodified 7K Zeba resins, respectively. Lanes 3A and 4A, which represent the 40K blend (1:1) and 7K blend (1:1), show no or very little free fluorescein bands at the bottom, indicating the excellent free dye removal properties of these two blends. Similarly, lanes 3B and 4B, which represent the 40K blend (1:1) and 7K blend (1:1), show no or very little free Alexa Fluor™ 555 bands at the bottom, indicating the excellent free dye removal properties of these two resins. Lanes 5A and 5B show complete disappearance of GAR antibody-conjugated fluorescein (5A) and GAM antibody-conjugated Alexa Fluor™ 555 (5B), as evidenced by the lack of reduction in the antibody bands in 5A and 5B on the gel. Lanes 3A, 4A, and 3B and 4B show excellent protein recovery of antibody-conjugated fluorescein and antibody-conjugated Alexa Fluor™ 555, in addition to removal of free dye.Bands from these lanes were quantified using iBright Analysis software and the % dye removal and % antibody dye conjugate recovery were plotted for the different resins (see data in Figures 15 and 16).

[0171] Example 5: Blend Composition for Removal of Small Molecule Reducing Agents 13 shows exemplary small molecule reducing agent removal data using a blend composition, device, kit, and method according to one embodiment of the present disclosure. The experiment is as follows: Reducing Agent Removal Protocol: 1. Pipette 714 μl of 70% resin slurry into the spin column in the collection tube. 2. Spin out the liquid at 1000×g for 2 minutes. 3. Replace the collection tube and add 100 μl of TCEP sample (25 mM) 1 mg / ml goat anti-rabbit antibody in PBS to each spin column for each sample. 4. Centrifuge at 1000×g for 2 minutes to remove TCEP from the samples.

[0172] Assessment of TCEP removal by Ellmans assay: 1. Measure amount of TCEP by adding the following to each sample in a 96-well plate: 2. 250 μl Ellmans buffer, 3. 10 μl Ellmans reagent (4 mg / ml), 4. 50 μl sample (diluted 1:10). 5. Read samples at 450 nm in a Multiskan plate reader and access protein recovery by A280 nm. 6. Pipette 4 μL sample onto a Nanodrop One and measure A280 nm.

[0173] Figure 13 is a bar graph showing the removal of the reducing agent TCEP using 7K and 40K blends (blended with dextran and PEG-diamine chemistry in a 1:1 ratio). TCEP removal is compared to unmodified 7K and 40K size-exclusion resins, as well as a non-size-exclusion column containing the FF4 blend. The black bars indicate the percent of protein recovered. The gray bars indicate the amount of TCEP removed in percent. The 40K and 7K resins remove 7.3% and 1.8% of the TCEP, while the 40K and 7K blends remove 98.5% and 88.7% of the TCEP. The FF4 blend, a blend made with a non-size-exclusion resin, removes 42.7% of TCEP. The FF4 blend also has a lower relative recovery of protein (36.4%) compared to the 40K and 7K blends, which show relatively good protein recoveries of 68.9% and 72.3%.

[0174] Example 6: Blend composition for removing small molecule biotin Figure 14 shows the removal of free / unreacted biotin using the 7K and 40K blends of the present disclosure. The experiment is as follows:

[0175] Biotin Removal Protocol: 1. Pipette 1 ml of 50% resin slurry into the spin column located in the collection tube. 2. Spin out the liquid at 1000 x g for 2 minutes. 3. Change the collection tube and add the biotinylated antibody samples to each spin column for each sample. 4. Centrifuge at 1000 x g for 2 minutes to remove free biotin from the samples.

[0176] Assessment of biotin removal: 1. The amount of biotin was measured by adding the following to each sample in a cuvette: a) 800 μl PBS buffer, b) 100 μl colorimetric HABA, c) 100 μl sample (diluted 1:10). 2. Samples were read at 500 nm on a Multiskan plate reader.

[0177] Assess recovery of biotinylated proteins: 1. Pipette 10 μl of sample onto a 96-well plate. 2. Prepare Pierce™ Rapid Gold BCA Protein Assay Working Reagent according to manufacturer's instructions. 3. Add 200 μl of Working Reagent to wells. 4. Incubate plate at room temperature for 5 minutes. 5. Read absorbance at 480 nm on a Multiskan plate reader.

[0178] Figure 14 is a bar graph showing the removal of free or unreacted biotin using the 7K and 40K blend (described in the previous example) compared to the removal of free biotin using unmodified 7K and 40K resins and the FF4 blend (described in the previous example). The black bars indicate the % protein recovery (of GAM Ab), and the gray bars indicate the amount of free biotin removed as a percentage. As shown, the unmodified 40K and 7K supports remove 40% and 38.75% of the free biotin, respectively, while the 40K and 7K blends remove 80.31% and 72.7% of the unreacted or free biotin, respectively. The FF4 blend (non-size-exclusion blend) shows 89.49% biotin removal. However, the FF4 blend has poor protein recovery, showing 21.4% protein recovery. In comparison, the 40K and 7K blends show good protein recovery.

[0179] Figures 12, 13, and 14 show the relatively superior removal of small molecules, including exemplary dyes, biotin, and reducing agents, using the modified 40K and 7 blends compared to using unmodified 40K and 7K size-exclusion columns. Protein recovery using a non-exclusion resin such as FF4 is relatively poor.

[0180] Example 7: Blend Composition for Removing Small Molecules Figures 12, 13, and 14 show the relatively superior removal of small molecules, including exemplary dyes, biotin, and reducing agents, using the modified 40K and 7K blends compared to using unmodified 40K and 7K size-exclusion columns. Protein recovery using a non-exclusion resin such as FF4 is relatively poor.

[0181] Additional experiments were also performed using the cross-linker succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), and the results are summarized in Table 2 below.

[0182] Table 2 shows the % protein recovery using the various blends described in the examples above for several different small molecules, including dye (fluorescein), biotin, TCEP, and SMCC. As can be seen, the blend containing the non-size-exclusion resin FF4 has the lowest protein recovery for all small molecules. Although biotin was removed by FF4 (as shown in Example 8), the protein recovery is less than optimal. [Table 2]

[0183] Figures 15 and 16 are bar graphs from experiments showing quantified bands from gels corresponding to Figure 12 to determine protein recovery and Alexa Fluor™ 555 removal, % protein recovery, and % free dye removal from the compositions tested. Gray bars indicate % dye removal, and black bars indicate % protein recovery. As shown in Figures 15 and 16, unmodified size-exclusion resins 40K Zeba and 7K Zeba resins were unable to efficiently remove free fluorescein or free Alexa Fluor™ 555. In contrast, the modified 40K and 7K blend compositions of the present disclosure were able to remove over 96% fluorescein and over 93% Alexa Fluor™ 555. The non-size-exclusion FF4 blend showed poor protein recovery of both the GAR-fluorescein-conjugated protein and the GAM-Alexa Fluor™ 555-conjugated protein, with protein recoveries of 15.5% and 14.5%, respectively.

[0184] The experimental steps for Figure 17 are as follows: 1. Prepare a 1.33 mM BS3 crosslinker solution in PBS. 2. Pipette 1 mL of 50% resin slurry into the spin columns located in the collection tubes. 3. Spin out the liquid at 1000 x g for 2 minutes. 4. Replace the collection tube and add BS3 solution to each spin column. 5. Remove BS3 by centrifugation at 1000 x g for 2 minutes.

[0185] Assess BS3 removal. 1. Prepare a 1:50 dilution of each flow-through sample in PBS by mixing 50 μl of flow-through with 450 μl of PBS. 2. Read samples at 280 nm on a UV Cary in a 500 μl cuvette.

[0186] To assess recovery of BS3 cross-linked proteins: 1. Pipette 10 μl of sample onto a 96-well plate. 2. Prepare Pierce™ Rapid Gold BCA Protein Assay Working Reagent according to manufacturer's instructions. 3. Add 200 μl of Working Reagent to wells. 4. Incubate plate at room temperature for 5 minutes. 5. Read absorbance at 480 nm on a Multiskan plate reader.

[0187] The experimental steps for Figure 17 are as follows: 1. Prepare a 1.33 mM SMCC crosslinker solution in PBS. 2. Pipette 1 mL of 50% resin slurry into the spin columns located in the collection tubes. 3. Spin out the liquid at 1000 x g for 2 minutes. 4. Replace the collection tube and add SMCC solution to each spin column. 4. Remove the SMCC by centrifugation at 1000 x g for 2 minutes.

[0188] Assess SMCC removal: 1. Prepare a 1:50 dilution of each flow-through sample in PBS by mixing 50 μl of flow-through with 450 μl of PBS. 2. Read samples at 280 nm on a UV Cary in a 500 μl cuvette.

[0189] Assess recovery of SMCC cross-linked proteins: 1. Pipette 10 μl of sample onto a 96-well plate. 2. Prepare Pierce™ Rapid Gold BCA Protein Assay Working Reagent according to manufacturer's instructions. 3. Add 200 μl of Working Reagent to wells. 4. Incubate plate at room temperature for 5 minutes. 5. Read absorbance at 480 nm on a Multiskan plate reader.

[0190] Figures 17 and 18 are bar graphs showing the removal of small molecules used as crosslinkers, including bis(sulfosuccinimidyl)suberate (BS3) and succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), using these resins. Figure 17 shows the removal of the BS3 crosslinker, and Figure 18 shows the removal of the SMCC crosslinker. In Figure 17, the gray bars correspond to % BS3 removal, showing that unmodified 40K and 7K Zeba resins remove 69.1% and 63.7% of the BS3 crosslinker, while the present compositions, including the 40K and 7K blends, remove 85.9% and 88% of the BS3 crosslinker. The FF4 blend removes 80% of the BS3, but the protein recovery characteristic of FF4 is only approximately 51%. In contrast, the present compositions, including the 40K and 7K blends, have protein recoveries of 80.6% and 89.7%.

[0191] In Figure 18, the gray bars indicate % SMCC removal, showing that unmodified 40K and 7K Zeba resins remove 61.6% and 53.7% of the SMCC crosslinker, while the present composition blends of 40K and 7K remove 85.9% and 89.4% of the SMCC crosslinker, respectively. The present composition blends perform 20% better than the unmodified 7K and 40K. The FF4 blend removes 84.3% of the crosslinker, but the protein recovery characteristics of FF4 are relatively poor, recovering only 2% of the protein. In contrast, the 40K and 7K blends show 63.1% and 83.8% protein recovery.

[0192] The present inventors have also shown that compositions of the present disclosure, including blends of dextran and PDA moieties and blends of dextran and EDA moieties immobilized on a size-exclusion support, can remove significant amounts of reducing agents such as dithiothreitol (DTT). This is illustrated in Figure 19, where the black bars indicate the percent removal of DTT and the gray bars indicate the percent protein recovery of goat anti-rabbit IgG. The 7K resin removed more than 95% of DTT, with a protein recovery of more than 85%.

[0193] Example 8: Compositions of the present disclosure versus other existing products for protein recovery and removal of small molecules (dyes, biotin, reducing agents) The compositions of the present disclosure showed better performance with excellent protein recovery for removal of dyes, biotin, and reducing agents when compared to columns containing other existing products sold for similar applications.

[0194] Figures 20A and 20B show the use of spin columns containing the disclosed compositions or products from other suppliers sold for similar applications, as well as standard dialysis, to compare dye removal and protein recovery. Spin columns containing the disclosed compositions or products from other suppliers were used to remove free Alexa Fluor™ 647 dye from a 100 μl sample of 10 mg / mL goat anti-rabbit IgG labeled with a 10 molar excess of Alexa Fluor™ 647. Equal amounts of sample from each flow-through and starting sample (lane 7) were loaded onto the gel. iBright Analysis Software was used to quantify free dye removal after the samples were run on an electrophoresis gel and imaged on an iBright FL1500 Imaging System (Thermo Fisher Scientific).

[0195] FIG. 20A shows an electrophoresis gel with: Lane 1: spin column containing a composition of the present disclosure for dye and biotin removal, Lane 2: BioRad P-30, Lane 3: G-Biosciences GT-100, Lane 4: G-Biosciences GT-600, Lane 5: GE PD10, Lane 6: Thermo Scientific Slide-A-Lyzer G2 Dialysis Cassette, 3.5K MWCO, Lane 7: (positive control) starting sample, 10 mg / ml goat anti-rabbit IgG 10 molar excess Alexa Fluor™ 647.

[0196] FIG. 20B shows graphical data illustrating dye removal and protein recovery for spin columns including: the disclosed composition for small molecule removal (first set of bars), BioRad P-30 (second set of bars labeled "BR"), G-Biosciences GT-100 (third set of bars labeled "GB1"), G-Biosciences GT-600 (fourth set of bars labeled "GB6"), GE PD10 (fifth set of bars labeled "GE").

[0197] As can be seen in Figures 20A and 20B, the spin columns of the present disclosure provide higher dye removal with superior protein recovery when compared to products from other suppliers.

[0198] FIG. 21 shows the use of spin columns containing compositions of the present disclosure or products from other suppliers sold for similar applications to compare biotin removal and protein recovery.

[0199] Biotin was removed using a spin column containing the composition of the present disclosure or a spin column containing a product from another supplier. 0.27 mM free NHS-LC-biotin was present in 100 μl of the sample. Protein recovery of 20× NHS-LC-biotin-labeled goat anti-mouse (2 mg / mL) was assessed using the Pierce™ Rapid Gold BCA Assay Kit (Thermo Fisher Scientific, Cat. No. A53225). Free biotin removal was quantified using the Thermo Scientific Biotin Quantification Kit (Thermo Fisher Scientific, Cat. No. 28005).

[0200] FIG. 21 shows graphical data illustrating biotin removal and protein recovery for spin columns including: the disclosed composition for small molecule removal (first set of bars), BioRad P-30 (second set of bars labeled "BR"), G-Biosciences GT-100 (third set of bars labeled "GB1"), G-Biosciences GT-600 (fourth set of bars labeled "GB6"), GE PD10 (fifth set of bars labeled "GE").

[0201] As can be seen in Figure 21, the spin columns of the present disclosure provide higher biotin removal and higher protein recovery when compared to products from other suppliers.

[0202] FIG. 22 illustrates the use of spin columns containing compositions of the present disclosure or products from other suppliers sold for similar applications to compare reducing agent removal.

[0203] The reducing agent TCEP was removed from 1 mg / mL goat anti-rabbit IgG containing 25 mM TCEP in PBS using a spin column containing the composition of the present disclosure or a spin column containing a product from another supplier. Removal of the reducing agent was performed by applying 700 μl of sample to a 2 mL column. Quantification of TCEP removal from the flow-through compared to the starting sample was performed using an Ellman assay.

[0204] 22 illustrates graphical data showing TCEP removal for spin columns including: the disclosed composition for small molecule removal (first set of bars), BioRad P-30 (second set of bars labeled "BR"), G-Biosciences GT-100 (third set of bars labeled "GB1"), G-Biosciences GT-600 (fourth set of bars labeled "GB6"), GE PD10 (fifth set of bars labeled "GE"). As can be seen, the %TCEP removal was much higher in the spin column including the disclosed composition when compared to the other spin columns tested.

[0205] Example 9: Disclosed Compositions vs. Dialysis for Removal of Small Molecules (Dyes and Biotin) The composition of the present disclosure was compared with dialysis, a standard method used in the art to purify small molecule impurities from proteins. The composition of the present disclosure showed better performance in removing dyes and biotin, with higher protein recovery in a fraction of the time required for dialysis.

[0206] As shown in Figure 23, a spin column containing a composition of the present disclosure for small molecule removal was compared to standard dialysis to remove free Alexa Fluor™ 647 dye from a sample of 10 mg / mL goat anti-rabbit IgG labeled with Alexa Fluor™ 647 (10 molar excess). Protein recovery was assessed by A280 measurement of the starting sample and the flow-through after dye removal. iBright Analysis Software was used to quantitate free dye removal after samples were run on an electrophoresis gel and imaged on an iBright FL1500 Imaging System (Thermo Fisher Scientific, product number A44241).

[0207] As can be seen in the graphical data of Figure 23, dye removal and protein recovery of spin columns containing the disclosed compositions for small molecule removal (first set of bars) were superior to those for dialysis. Furthermore, the disclosed spin column method takes only 15 minutes, compared to overnight with three buffer exchanges for dialysis. Thus, the present compositions and methods provide surprisingly pure protein and small molecule removal in a one-step process that is significantly faster than dialysis.

[0208] Figure 24 shows data for a spin column containing a composition of the present disclosure for small molecule removal compared to standard dialysis to remove free NHS-LC-biotin. Protein recovery of goat anti-rabbit (2 mg / mL) labeled with 20X NHS-LC-biotin was assessed by the Rapid Gold BCA Test (Thermo Fisher Scientific, product number A53225).

[0209] As can be seen in the graphical data of Figure 24, biotin removal and protein recovery for the spin column containing the disclosed composition for small molecule removal (first set of bars) was superior to that for dialysis. Furthermore, the method using the disclosed spin column took only 15 minutes, compared to overnight with three buffer exchanges for dialysis. Thus, the compositions and methods of the present invention provide surprisingly pure protein and small molecule removal in a one-step process that is significantly faster than dialysis.

[0210] Example 10: Compositions of the present disclosure in a spinplate device for removing small molecules To test the removal of small molecules, compositions of the present disclosure were placed in a spin plate device. In some embodiments, to test the high-throughput removal of small molecules from multiple samples, compositions of the present disclosure were placed in a 96-well filter plate.

[0211] As can be seen in Figure 25, a composition of the present disclosure for removing small molecules was placed in a 96-well filter plate to remove free Alexa Fluor™ 647 dye from 50 μl (lanes 1 and 2) and 100 μl samples (lanes 3 and 4) of 10 mg / mL goat anti-rabbit IgG labeled with a 10 molar excess of Alexa Fluor™ 647. Equal amounts of sample from each flow-through and starting sample (lane 5, positive control) were loaded onto the gel. iBright Analysis Software was used to quantify free dye removal after the samples were run on an electrophoresis gel and imaged on an iBright FL1500 Imaging System (Thermo Fisher Scientific, product number A44241). Dye removal and excellent protein recovery were demonstrated.

[0212] Example 11: Compositions of the present disclosure for the removal of small molecule fluorescein dyes The compositions of the present disclosure were placed in a spin column and tested for removal of fluorescein dye.

[0213] As can be seen in Figure 26, a composition of the present disclosure for removing small molecules was placed in a spin column to remove free fluorescein dye (Thermo Fisher Scientific catalog number 46410) from a 100 μl sample of 10 mg / mL goat anti-rabbit IgG labeled with a 15 molar excess of fluorescein. Equal amounts of sample from each flow-through (lanes 1-3) and the starting sample (lane 4) were loaded into the gel. iBright Analysis Software was used to quantify free dye removal after the samples were run on an electrophoresis gel and imaged on an iBright FL1500 Imaging System (Thermo Fisher Scientific, product number A44241). Dye removal and excellent protein recovery were demonstrated.

[0214] Example 12: Compositions of the disclosure for immunofluorescence applications The compositions, devices and methods of the present disclosure have been found to be useful in immunofluorescence applications.

[0215] In one example, HDAC2 polyclonal antibody (Thermo Fisher Scientific, product number PA1-861) was labeled with Alexa Fluor™ 647 (Thermo Fisher Scientific, product number A20006) and then purified from unreacted dye using a spin column containing the composition of the present disclosure to remove small molecules. Figures 27A and 27B show immunofluorescence analysis of HDAC2 (red) in A549 cells. Cells were fixed with 4% paraformaldehyde in PBS for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes, and blocked with 1% BSA in PBS. Cells were stained with HDAC2 polyclonal antibody, Alexa Fluor™ 647 conjugate, at a dilution of 2.5 μg / ml in blocking buffer for 1 hour at room temperature, protected from light, with cleanup using a spin column containing a composition of the present disclosure of unreacted dye (FIG. 27B) and without cleanup by not using a spin column of the present disclosure (FIG. 27A).

[0216] As can be seen, Figure 27A shows a lot of background fluorescence compared to Figure 27B, which significantly reduced the residual background.

[0217] In another example, cleanup of small molecule dyes in immunofluorescence assays was compared to cleanup using existing products marketed for similar applications.

[0218] PMP70 polyclonal antibody (Thermo Fisher Scientific, product number PA1-650) was labeled with Alexa Fluor™ 647 (Thermo Fisher Scientific, product number A20006) and then purified from unreacted dye using a spin column containing a composition of the present disclosure to remove small molecules. Immunofluorescence analysis of PMP70 (although the red color in the original is shown here in black and white) in A549 cells was performed as follows: Cells were fixed with 4% paraformaldehyde in PBS for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes, and blocked with 1% BSA in PBS. Cells were stained with PMP70 monoclonal antibody, Alexa Fluor™ 647 conjugate, at a dilution of 2.5 μg / ml in blocking buffer for 1 hour at room temperature, protected from light, with 1) no cleanup of unreacted dye (FIG. 28A), 2) cleanup using a conventional GE PD-10 column (FIG. 28B), and 3) cleanup using the disclosed spin column (FIG. 28C). Nuclei (blue in the original, shown here in black and white) were stained with Hoechst dye at a dilution of 10,000 in blocking buffer.

[0219] As can be seen, Figure 28A shows a lot of background immunofluorescence, a reduction in background fluorescence is seen in Figure 28B, and Figure 28C shows significant residual background fluorescence indicating excellent cleanup of the dye using the spin columns of the present disclosure.

[0220] In yet another example, ZO-1 monoclonal antibody (Thermo Fisher Scientific, product number MA3-39100) was labeled with Alexa Fluor™ 488 (Thermo Fisher Scientific, product number A20000) and then purified from unreacted dye using a spin column containing the disclosed composition for removing small molecules. Immunofluorescence analysis of ZO-1 (green in the original, shown here in black and white) was performed on Caco-2 cells. Cells were fixed with 4% paraformaldehyde in PBS for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes, and blocked with 1% BSA in PBS. Cells were stained with ZO-1 polyclonal antibody, Alexa Fluor™ 488 conjugate, at a dilution of 5 μg / ml in blocking buffer for 1 hour at room temperature, protected from light, with cleanup using a spin column containing a composition of the present disclosure (FIG. 29B) and without cleanup by not using a spin column of the present disclosure (FIG. 29A).

[0221] As can be seen, Figure 29A shows a lot of background fluorescence compared to Figure 29B, which significantly reduced the residual background.

[0222] Example 14: Composition of the disclosed counterion exchange resin for protein recovery and small molecule removal All experiments for removing small molecules (in this example) were performed using a 0.5 mL resin bed volume (of various chemistries as described above and below) assembled into a 0.8 mL spin column to create a device according to a non-limiting embodiment of the present disclosure. In this particular example, the spin column was filled with either the composition of the present disclosure (labeled Roomba in the corresponding figure) or the ion exchange resin Dowex. The spin column was spun at 1000 x g for 2 minutes to remove the storage solution. The spin column was then placed into a clean 2 mL centrifuge tube. Sample volumes of 50 μL, 250 μL, and 400 μL were added to the center of the resin, the column was spun at 1000 x g for 2 minutes, and the flow-through was collected in a 2 mL tube. 10 μL of the flow-through was added to 90 μL of sample buffer. 10 μL of this was then added per well to a 4-20% Tris-Glycine-SDS gel. The gel was run for 40 minutes and then imaged using an iBright imager (Thermo Fisher Scientific).

[0223] Two concentrations of goat anti-rabbit Alexa Fluor™ 594 conjugate ("GAR-594") were used in this experiment: 1 mg / mL (gel shown in Figure 30A) and 10 mg / mL (gel shown in Figure 31A).

[0224] Carrier lanes 1-3 used in Figures 30A, 30B, 31A and 31B used dextran PEG diamine blend (composition of the present disclosure), labeled Roomba in Figures 30A-31B.

[0225] Lanes 4 to 6 use Dowex (unmodified ion exchange resin).

[0226] Volumes of antibody-dye conjugates used in Figures 30A, 30B, 31A and 31B. Lane 1 and Lane 4 - 50 μl

[0227] Lane 2 and Lane 5 - 250 μl

[0228] Lane 3 and Lane 6 - 400 μl

[0229] Starting lane - Uncleared sample (10 mg / mL GAR-594 conjugate Figure 30A or 1 mg / mL GAR-594 conjugate Figure 31B)

[0230] The results of these experiments are illustrated in the gels of Figures 30A and 31B and the bar graphs of Figures 30B and 31B.

[0231] Figures 30A and 30B illustrate the removal of free dye Alexa Fluor™ 594, another exemplary small molecule, when 10 mg / mL dye-antibody conjugate in different volumes (50 μl, 250 μl, and 400 μl) is applied to spin columns with different carriers: a composition of the present disclosure, a dextran PEG 20K blend (labeled Roomba in Figures 30A and 30B), and a pure ion exchange resin (unmodified ion exchange resin), Dowex.

[0232] The lane labeled "Start" represents an "uncleaned" sample run as described in the previous section (this corresponds to a positive control in which unbound dye from the protein mixture is not spun down to remove the dye). The top two bands in lane "Start" correspond to the reduced antibody (light and heavy chains). The bottom band corresponds to the free dye, Alexa Fluor™ 594. In Figure 30A, lanes 1, 2, and 3 show good protein recovery when comparing the top two bands to the "Start" lane. Furthermore, the bottom free dye band is missing in lanes 1-3, indicating removal of free dye by the spin column using the resin composition of the present disclosure. In comparison, lane 4 shows loss of protein recovery by the ion exchange resin when 50 μl of the conjugate is added to an unmodified ion exchange resin bed. This shows that adding 10 mg / mL of GAR-Alexa Fluor™ 594 conjugate to 50 μl to 500 μl of resin bed, where the resin bed has the composition of the present disclosure, is a dextran-PEG diamine resin blend, and good recovery is obtained with the dextran-PEG diamine blend, but protein yield is lost with the Dowex resin. Graphs generated using iBright Analysis Software match the images very well.

[0233] FIG. 31A illustrates the removal of free small molecule dye Alexa Fluor™ 594 using different carriers, namely, the composition of the present disclosure, dextran PEG 20K blend, and pure ion exchange resin (unmodified ion exchange resin), Dowex, upon addition of different volumes (50 μl, 250 μl, and 400 μl) of 1 mg / mL dye-antibody conjugate.

[0234] The lane labeled "Start" represents an "uncleaned" (positive control) sample processed as described in the previous section. The top two bands in lane "Start" correspond to the reduced antibody (light and heavy chains). The bottom band corresponds to the free dye Alexa Fluor™ 594. Lanes 1, 2, and 3 in Figure 31A show good protein recovery when comparing the top two bands to the "Start" lane. Additionally, lanes 1-3 lack the lower free dye band, indicating removal of free dye by the disclosed composition. Lanes 4, 5, and 6 show loss of protein recovery by the ion exchange resin when 1 mg / mL antibody-dye conjugate is added to the resin bed at 50 μl, 250 μl, and 400 μl. This shows lower protein recovery on the Dowex resin compared to the dextran-PEG diamine blend resin at all volumes tested: 50 μl, 250 μl, and 400 μl of GAR-Alexa Fluor™ 594 conjugate at 1 mg / mL. Graphs generated using iBright Analysis Software match the images very well.

[0235] The bar graphs shown in Figures 30B and 31B quantitate the percentage of protein recovery and the percentage of dye removed, and demonstrate greater than 90% protein recovery using the composition of the present disclosure (shown as Roomba in Figures 30B and 31B) when loading 0.05 mg to 4 mg of GAR 594 Ab-dye conjugate with greater than 90% dye removal.

[0236] In comparison, Dowex provides >90% protein recovery with >90% dye removal, but only at lower scales and with much higher protein concentrations, i.e., when 2.5 mg–4 mg of GAR594 Ab-Dye conjugate is loaded.

[0237] This data indicates that the compositions of the present disclosure offer approximately 50-fold greater flexibility, allowing protein recovery over a wider range of sample protein concentrations and volumes compared to unmodified ion-exchange-only resins (such as Dowex).

[0238] Thus, this example demonstrates that the compositions of the present disclosure achieve high protein recovery and efficient small molecule removal (removal of virtually all small molecules) across a wide range of low and high sample protein concentrations and high and low sample protein volumes. In contrast, the ion exchanger Dowex is limited in that it only works with high sample protein concentrations and high protein volumes, but does not efficiently remove small molecules or have high protein recovery at low sample protein volumes and concentrations. Advantageously, the compositions, devices, and methods of the present invention provide much higher protein recovery, even when purifying very low concentrations of sample protein from small molecule contaminants.

[0239] The above experiments were performed using Dowex or the composition of the present disclosure placed in a spin column. In other experiments (data not shown), batch processing for small molecule removal was performed in large batches for the composition of the present disclosure versus Dowex. The method involved taking a large batch of dry resin, either the composition of the present disclosure or Dowex, adding the conjugated protein to the small molecule, which may contain free, floating small molecule contaminants (such as antibody-dye conjugates), mixing the dried resin with the protein conjugated to the small molecule, and recovering the conjugated protein in the filtrate, where free, unbound small molecules bind to Dowex or the composition of the present disclosure. It should be noted that in these experiments, the use of a pure ion exchange column, Dowex, required a pH change (lowering the pH) to allow the ion exchanger to bind small molecules. This additional pH change step was not necessary for the composition of the present disclosure. Therefore, a further advantage of the composition of the present disclosure is the reduced number of steps and ease of separation. ********

[0240] Each embodiment disclosed herein may be used or otherwise combined with any of the other disclosed embodiments. Any element of any embodiment may be used in any embodiment. While the claimed embodiments have been described with reference to certain exemplary embodiments, it will be understood by those skilled in the art that various changes may be made and elements may be substituted with equivalents without departing from the true spirit and scope of the claimed invention. Furthermore, modifications may be made without departing from the essential teachings of the invention. Another aspect of the present invention may be as follows. [1] A composition for separating one or more small molecules from a sample, comprising: a size exclusion support; and at least one moiety capable of binding to said one or more small molecules. [2] The composition described in [1], wherein the at least one moiety is bound to the size-exclusion carrier. [3] The composition described in [2], wherein at least the portion is immobilized on the size exclusion carrier. [4] The composition described in [1] above, further comprising at least a second size-exclusion carrier and at least a second portion. [5] The composition according to [1], comprising at least two parts. [6] The composition of [1], wherein the at least one moiety comprises a polysaccharide, a dextran, a polyethylene glycol polymer, an amine-containing polymer, a polyamino acid, a lipopolysaccharide, an antibiotic, a chelating group, a magnetic particle, a paramagnetic particle, a functional group, an ion exchanger, and combinations thereof. [7] The composition according to [6], wherein the amine-containing polymer is poly(ethylene glycol) diamine, polyethylene diamine, linear polyethyleneimine, or branched polyethyleneimine. [8] The composition according to [7], wherein the linear polyethyleneimine is diethylenediamine. [9] The composition described in [6], wherein at least one of the moieties is dextran.

[10] The composition described in [9], wherein the dextran has a molecular weight in the range of approximately 6 kDa to 2800 kDa.

[11] The composition of [1], wherein the at least one moiety binds to the one or more small molecules by charge interaction, hydrophilic interaction, hydrophobic interaction, affinity interaction, hydrogen bonding, or van der Waals forces.

[12] The composition described in [1], wherein the one or more small molecules have a molecular weight range of less than 2000 Da.

[13] The composition of [1], wherein the one or more small molecules include dyes, dye derivatives, biotin, biotin derivatives, crosslinkers, reducing agents, labels, nanoparticles, radioligands, mass tags, unreacted molecules, and combinations, intermediates, and derivatives thereof.

[14] The composition described in [1], wherein the size exclusion carrier comprises a dextran polymer, agarose, polyacrylamide, a cellulose material and / or a derivative thereof, hydroxyethyl cellulose, or a derivative of hydroxyethyl cellulose.

[15] The composition of [1], wherein the sample contains a biomolecule, a protein, a glycoprotein, an antibody, a peptide, a nucleic acid, a polysaccharide, a carbohydrate, or a lipid, and contacting the sample with the composition substantially reduces the amount of the one or more small molecules from the sample.

[16] A device for separating one or more small molecules from a sample, comprising: a) a container containing at least one size exclusion support and at least one moiety capable of binding to said one or more small molecules; b) a receptacle located below the container.

[17] The device described in

[16] , configured to be operable to receive gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, and combinations thereof.

[18] The device described in

[16] , wherein the container is a columnar container, a tube, a multi-well tube, a multi-well plate, or a multi-well filter plate.

[19] The device described in

[16] , wherein the at least one moiety is immobilized on, attached to, or bound to a size exclusion resin.

[20] The device described in

[19] , wherein the at least one moiety is attached to the size exclusion resin by a covalent interaction.

[21] The device described in

[16] , wherein the at least one portion is bound to the one or more small molecules by charge interaction, hydrophilic interaction, hydrophobic interaction, affinity interaction, hydrogen bond, van der Waals force, or covalent bond.

[22] The device described in

[16] , wherein the at least one moiety capable of binding one or more small molecule impurities comprises a polysaccharide, a dextran, a polyethylene glycol polymer, an amine-containing polymer, a polyamino acid, a lipopolysaccharide, an antibiotic, a chelating group, a magnetic particle, a paramagnetic particle, a functional group, and combinations thereof.

[23] The device according to

[16] , wherein the amine-containing polymer is poly(ethylene glycol) diamine, polyethylene diamine, linear polyethyleneimine, or branched polyethyleneimine.

[24] The device described in

[23] , wherein the linear polyethyleneimine is diethylenediamine.

[25] The device described in

[22] , wherein the portion is dextran.

[26] The device described in

[22] , wherein the portion is an ion exchanger.

[27] The device described in

[26] , wherein the ion exchanger is an anion exchanger or a cation exchanger.

[28] The device described in

[16] , wherein the size exclusion resin excludes molecules of 2 kDa or larger from the sample.

[29] The device described in

[16] , wherein the one or more small molecules include dyes, dye derivatives, biotin, biotin derivatives, crosslinkers, reducing agents, labels, nanoparticles, radioactive ligands, mass tags, unreacted molecules, and combinations, intermediates, and derivatives thereof.

[30] The device described in

[16] , wherein the small molecule substance has a molecular weight of less than 2000 Da.

[31] The device described in

[16] , wherein the sample contains proteins, polysaccharides, nucleic acids, carbohydrates, lipids, glycoproteins, antibodies, peptides, toxins, nanoparticles, and conjugates and derivatives thereof.

[32] The device described in

[16] , wherein a first size-exclusion carrier binds to a first portion and a second size-exclusion carrier binds to a second portion, and the first size-exclusion carrier and the second size-exclusion carrier are the same or different size-exclusion carriers.

[33] The device described in

[32] , wherein the first size-exclusion carrier is bound to a first portion comprising an amine-containing polymer, and the second size-exclusion carrier is bound to a second portion comprising dextran.

[34] The device described in

[32] , wherein the first size-exclusion carrier is bound to a first moiety comprising poly(ethylene glycol) diamine, polyethylene diamine, linear polyethyleneimine, or branched polyethyleneimine.

[35] The device described in

[34] , wherein the first size-exclusion carrier is bound to a first moiety comprising diethylenediamine.

[36] A system for separating one or more small molecules from a sample, comprising: a) a container containing a size exclusion support and at least one moiety capable of binding to said one or more small molecules; b) a receptacle located below the container; and c) means for subjecting said containers and receptacles to gravity flow, centrifugal force, positive pressure, negative pressure, vacuum and combinations thereof.

[37] A kit for separating a biomolecule from one or more small molecules, comprising: a device, the device comprising: a) a vessel containing a size exclusion resin and at least one moiety capable of binding to and capturing said at least one small molecule; b) a receptacle located below the container; The kit, wherein the device is operatively configured to receive gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, and combinations thereof.

[38] The kit according to

[37] , comprising at least two or more moieties capable of binding to the one or more small molecules.

[39] The kit according to

[37] , wherein the device is a spin column, a multi-well filter plate, or a multi-well plate.

[40] The kit according to

[35] , further comprising a buffer solution.

[41] A method for separating a biomolecule from one or more small molecules, comprising: a) applying a sample containing said biomolecules to a vessel containing a size exclusion resin and at least one moiety capable of binding said one or more small molecules; b) subjecting the container to gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, or a combination thereof, wherein the biomolecules in the sample are excluded by the size exclusion resin and collected as flow-through, and the one or more small molecules bind to the at least one moiety and are thereby separated from the biomolecules.

[42] The method according to

[41] , wherein the separation of the biomolecule from the at least one small molecule is carried out in the single step b).

[43] The method according to

[41] , wherein the flow-through is collected in a receptacle located below the vessel.

Claims

1. 1. A composition for separating one or more small molecules from a sample, comprising: at least one first size-exclusion carrier comprising polyacrylamide, a cellulose material, hydroxyethyl cellulose and / or derivatives thereof; at least one first moiety that is an amine-containing polymer and is immobilized on the at least one first size-exclusion support via a carbon-nitrogen bond; the at least one first moiety binds to the one or more small molecules; A composition wherein the one or more small molecules have a molecular weight of less than 2000 Da.

2. further comprising at least one second portion; 2. The composition of claim 1, wherein the at least one second portion is immobilized on the at least one first size-exclusion support and is different from the at least one first portion.

3. further comprising at least one second size exclusion carrier; the at least one first portion is immobilized on the at least one second size-exclusion support; The composition of claim 1 , wherein the at least one second size-exclusion carrier is different from the at least one first size-exclusion carrier.

4. The composition of claim 3 , wherein the second size-exclusion carrier comprises a dextran polymer or agarose.

5. 3. The composition of claim 2, wherein the at least one second moiety comprises a polysaccharide, a dextran, a polyethylene glycol polymer, an amine-containing polymer, a polyamino acid, a lipopolysaccharide, an antibiotic, a chelating group, a magnetic particle, a paramagnetic particle, a functional group, an ion exchanger, or a combination thereof.

6. 10. The composition of claim 1, wherein the amine-containing polymer is poly(ethylene glycol) diamine, polyethylene diamine, linear polyethyleneimine, or branched polyethyleneimine.

7. The composition of claim 5 , wherein the at least one second moiety is dextran.

8. 10. The composition of claim 1, wherein the one or more small molecules comprise a dye, a dye derivative, biotin, a biotin derivative, a crosslinker, a reducing agent, a label, a nanoparticle, a radioligand, a mass tag, an unreacted molecule, or any combination, intermediate, and derivative thereof.

9. 1. A device for separating one or more small molecules from a sample, comprising: a) a container containing the composition according to any one of claims 1 to 8; b) a receptacle located below the container; The device, wherein the vessel is a column vessel, a tube, a multi-well tube, a multi-well plate, or a multi-well filter plate.

10. 10. The device of claim 9, wherein the device is operatively configured to be subjected to gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, or a combination thereof.

11. 1. A method for separating at least one biomolecule from one or more small molecules, comprising: a) applying a sample containing said at least one biomolecule to a vessel containing a composition according to any one of claims 1 to 8; b) subjecting said vessel to gravity flow, centrifugal force, positive pressure, negative pressure, vacuum or any combination thereof, wherein: The at least one biomolecule in the sample is excluded by the at least one first size-exclusion carrier and collected as a flow-through; the one or more small molecules bind to the at least one first moiety and are thereby separated from the at least one biomolecule; the at least one biomolecule excluded from the sample is greater than 2 kDa; A method comprising:

12. 12. The method of claim 11, wherein the at least one first moiety binds to the one or more small molecules by charge interactions, hydrophilic interactions, hydrophobic interactions, affinity interactions, hydrogen bonds, or van der Waals forces.

13. 1. A system for separating one or more small molecules from a sample, comprising: a) a container containing the composition according to any one of claims 1 to 8; b) a receptacle located below the container; and c) means for subjecting said containers and receptacles to gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, or any combination thereof.

14. 1. A kit for separating a biomolecule from one or more small molecules, comprising: a device, the device comprising: a) a container containing the composition according to any one of claims 1 to 8; b) a receptacle located below the container; the device is operatively configured to receive gravity flow, centrifugal force, positive pressure, negative pressure, vacuum, or any combination thereof; The kit, wherein the device is a spin column, a multi-well filter plate, or a multi-well plate.

15. 15. The kit of claim 14, further comprising a buffer.

16. The composition of claim 1, wherein the at least one first moiety binds to the one or more small molecules by charge interactions, hydrophilic interactions, hydrophobic interactions, affinity interactions, hydrogen bonds, van der Waals forces, or any combination thereof.

17. The composition of claim 1, wherein the amine-containing polymer of the at least one first portion is diethylenediamine.

18. The composition of claim 2, wherein the at least one second portion is a dextran polymer having a molecular weight in the range of 6 kDa to 2800 kDa.

Images